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Abstract: Countermeasures against organophosphorus (OP) anticholinesterases 
(organophosphates) have been extensively investigated. One means of safeguarding 
against exposure to OP compounds is use of a prophylactic agent, which can be either 
enzyme- or inhibitor-based. Butyrylcholinesterase (BChE) has been shown to completely 
protect against OP intoxication by binding to toxicant molecules before reaching the 
target enzyme (acetylcholinesterase) in tissues. Its use, however, is limited due to the 
large amount of enzyme needed for effective protection. Reduction of the enzyme dose 
necessary for long-term use may be achieved by pharmacokinetic or pharmacodynamic 
means. The effects of 1) poly-l-lysine grafted poly(ethylene glycol) copolymer 
complexation and 2) re-engineering of enzyme surface loops on BChE related to 
prophylactic capacity (e.g. substrate and inhibitor kinetics, in vitro enzyme inactivation) 
were investigated. Complexation with PLL-g-PEG resulted in a decreased turnover 
number (kcat) with butyrylthiocholine (BTChI), but relatively similar bimolecular rate 
constants (ki) with paraoxon (7-12%). More extensive reductions in ki were noted with 
other inhibitors (up to 60%). Copolymer-complexed enzymes were also less sensitive to 
heat and protease-mediated enzyme inactivation. While PLL-g-PEG complexation may 
improve the in vivo pharmacokinetics of BChE, we also investigated a pharmacodynamic 
approach. A catalytic variant of BChE, G117H, has been previously developed, though 
its interaction with OP compounds is too slow to be toxicologically relevant. Five 
BChEG117H mutants were produced with a 3-residue insertion into an identified 
hypermobile surface loop on BChEG117H (278-285). While loop mutants displayed 
decreased catalytic activity against BTChI, one loop mutant (ENA variant) had a slight 
but significant increase in the enzyme’s reactivation rate (k3) with paraoxon (a 50% 
increase). In addition to enzyme-based strategies, we also investigated the inhibitor-based 
prophylactic drug pyridostigmine bromide (PB). PB is effective when used in conjunction 
with standard antidotes, though its pharmacokinetics are suboptimal. We 3) studied the 
ability of nanocrystalline cellulose hydrogel formulations (NCC-PB) as an oral PB 
delivery vehicle for enhanced dosing logistics. In vitro and in vivo evaluations of four 
NCC-PB formulations suggested that the time course of cholinesterase inhibition may be 
extended in comparison to free PB. Overall, these studies highlight a range of approaches 
aimed at improving both available and developing prophylactic agents against 
organophosphate toxicity.  
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 Organophosphorus (OP) compounds are a diverse class of chemicals both utilized 
as pesticides and exploited as agents of chemical warfare and terrorism. OP compounds 
share a common mechanism of action by inhibition of acetylcholinesterase (AChE) and 
subsequent overstimulation of the cholinergic system. During WWII several new OP 
compounds were developed, and their high human toxicity was quickly recognized [1]. 
These highly toxic OP compounds became known as nerve agents. Chemical warfare and 
terrorism attacks with nerve agents have been reported since the 1980s, with recent 
recognition due to their use in the murder of Kim Jong Nam (the former heir apparent to 
North Korea) and the attempted murder of former Russian spy Sergei Skripal in 2017 and 
2018, respectively [2-4]. While efforts to prevent the use of nerve agents have been 
largely effective, recent history suggests the threat of a nerve agent attack persists.
 Anticholinesterase toxicity manifests as excess salivation, gastrointestinal upset, 
muscle tremors and fasciculations, and difficulty breathing, with seizures and death 
occurring in more severe exposures [5]. Treatments are available to manage signs and 
symptoms of toxicity, though there is evidence that long-term neurological deficits persist 
following exposure, even when current treatments are administered [6]. Moreover, it is 
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important to recognize that severe exposures (with some compounds, milligram amounts) 
can cause death in less than 10 minutes. During a realistic exposure scenario, in these 
cases it is dubious that potentially life-saving treatments would be delivered within the 
necessary time frame. As a result, there is a need for countermeasures which can reliably 
prevent both lethality and neurological sequelae from severe OP intoxications. 
 One approach for improving the consequences of OP toxicity are prophylactic 
agents, which would be taken in cases when there is a perceived threat of nerve agent 
exposure. It is likely that this approach would only be utilized in individuals deemed 
high-risk for exposure, for example soldiers and military physicians. Despite this, highly 
effective prophylactic agents could conceivably improve outcomes during a civilian 
attack, as temporary resistance to OP toxicity in first responders could facilitate the 
emergency response.   
 Prophylaxis against OP toxicity can be carried out via acetylcholinesterase 
inhibitor- (e.g., a carbamate anticholinesterase) or enzyme- (e.g., butyrylcholinesterase) 
based strategies. Both types have demonstrated efficacy, though both face challenges 
relating to their pharmacokinetic and/or pharmacodynamic properties. We hypothesized 
that systematic modulation of inhibitor- and enzyme-based strategies by nanomaterial-
based formulation and computer modeling-driven protein re-engineering can improve 
their respective prophylactic properties. This project was divided into three aims, wherein 
three different strategies for improvement of prophylactic agents were evaluated.  
 Butyrylcholinesterase (BChE), a close relative of AChE, has been extensively 
investigated as a prophylactic agent. BChE stoichiometrically binds all OP compounds. 
Therefore, when BChE is present in large amounts it acts as a molecular sponge, 
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removing toxicant molecules from the circulation before reaching synaptic AChE 
molecules. Injected BChE is both safe and effective at preventing all adverse effects of 
OP exposure when administered in sufficient doses [7, 8]. Despite its effectiveness, there 
are economic barriers to the implementation of BChE as a prophylactic agent. One 
potential mechanism to overcome this barrier is development of modifications which 
prolong the circulation of BChE, thereby decreasing the necessary dosing frequency and 
total protein amount needed.  
 The goal of Aim 1 was to evaluate enzymatic properties of BChE in complex with 
a biodegradable poly-l-lysine graft poly(ethylene glycol)(PLL-g-PEG) copolymer of 
three different sizes. Modification of BChE with a PLL-g-PEG copolymer has the 
potential to improve pharmacokinetic properties of the enzyme [9, 10]. However, 
previous studies have demonstrated that PEG conjugation alone may alter enzymatic 
properties such as catalytic activity, protease sensitivity, and heat tolerance [11-13]. As 
these characteristics could have an impact on BChE’s prophylactic efficacy, we 
investigated the effect of PLL-g-PEG on these properties. Moreover, enzyme 
modifications aimed at improving the pharmacokinetic profile of BChE must not 
significantly hinder the enzyme’s ability to bind OP compounds. We therefore performed 
inhibitor kinetics and an in vitro scavenging assay to inform our final conclusions.  
 While complexation with PLL-g-PEG was aimed at improving BChE’s 
pharmacokinetic properties, the next approach was focused on improving 
pharmacodynamic interactions. Due to the stoichiometric nature of the reaction between 
BChE and OP compounds, a severe exposure to an anticholinesterase can overcome the 
protection provided by BChE. Therefore, enzyme prophylactics which are catalytically 
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active towards OPs would be superior, as they would require less total protein and are not 
consumed as a result of interaction with the OP. A single nucleotide mutant of BChE, 
G117H, has been previously developed and shown to hydrolyze multiple OP compounds; 
however, the turnover rate against OP molecules is too slow to be physiologically 
relevant [14]. Aim 2 sought to improve the turnover rate of BChEG117H using a molecular 
dynamics-based re-engineering strategy. The conceptual framework for this approach 
was based on previous findings that manipulation of catalysis-linked dynamic surface 
loops can increase enzymatic activity [15]. In this study, we identified a promising 
surface loop and produced mutant enzymes which contained a three-residue insertion in 
the sequence of interest. It was postulated that increasing the length of a dynamic peptide 
loop with hydrophilic residues could increase energy transfer from the solvent to the 
active site. These loop mutants were evaluated for catalytic activity against the model 
substrate butyrylthiocholine and selected OP anticholinesterases. Resistance to inhibition 
and enzyme reactivation assays were also performed to further elucidate the effect of our 
three-residue insertion on OP hydrolysis.  
 The final aim of this study focused on the inhibitor-based prophylactic, 
pyridostigmine bromide (PB). Pyridostigmine was used by soldiers as a prophylactic 
agent during the Persian Gulf War of 1991, and has been found to increase resistance to 
organophosphate-induced lethality by 40 times [16]. Importantly, however, if an 
individual is exposed to an OP compound while using PB protection, it is still necessary 
to seek traditional post-exposure treatments. This is in contrast to enzyme-based 
strategies which can work independently. Despite this drawback, inhibitor-based 
strategies are the only prophylactic agents currently approved for human use, and they are 
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a much more affordable option. While PB is given orally, it faces similar 
pharmacokinetic issues as BChE (i.e. a relatively short duration of action). Cellulose-
based hydrogels have been previously used to extend drug release in oral delivery 
systems [17, 18]. For our study, four nanocrystalline cellulose-PB formulations were 
produced and evaluated. Cholinesterase inhibition over time was used as a mechanism to 
evaluate the efficacy of the cellulose formulations to extend the release of PB, both in 







REVIEW OF LITERATURE 
 
 2.1 CHOLINERGIC SYSTEM 
The cholinergic system, of which acetylcholine (ACh) is the endogenous 
neurotransmitter, is a major signaling pathway in many organisms, including humans. In 
the 1920’s, Otto Loewi proved that synaptic signaling was mediated by chemical 
transmission. He demonstrated that fluid collected from a bath in which a heart-vagus 
nerve preparation was stimulated to slow the heart, could be transferred to a denervated 
heart in a separate bath and reduce that heart’s rate. Later Dale identified the substance in 
the fluid that reduced heart rate as acetylcholine. Both received the Nobel Prize for their 
contributions. Thus acetylcholine was the first identified neurotransmitter [19].  
In the central nervous system, cholinergic activity influences learning and 
memory, addiction, motor coordination, respiration, and thermoregulation, among other 
functions [20-23]. ACh also acts at the neuromuscular junction, where it is responsible 
for the stimulation of somatic muscle fibers [24]. Furthermore, the autonomic nervous 
system, which is split into the opposing sympathetic (i.e. flight-or-fight) and 
parasympathetic (i.e. rest and digest) branches, primarily uses cholinergic neurons to 
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innervate parasympathetic end organs [25]. Activation of the parasympathetic branch, 
mediated by cholinergic signaling (by both preganglionic and postganglionic neurons), 
results in decreased heart rate, miosis, increased gastrointestinal secretions and motility, 
urination, and many other effects. In contrast, only the preganglionic neurons 
of the sympathetic branch are cholinergic, with postganglionic signaling mediated by 
adrenergic neurons (i.e. norepinephrine-releasing). An exception to this is the eccrine 
sweat glands, whose postganglionic neurons are actually cholinergic. When sympathetic 
tone predominates, individuals experience increased blood pressure, adrenal stimulation, 
and diaphoresis, in addition to effects opposite those above (e.g. increased heart rate, 
mydriasis, inhibition of digestive functions, etc.).  
The general features of ACh synthesis and metabolism are the same in the central 
and peripheral systems. First, acetylcholine is synthesized from choline and acetyl-CoA 
in the presynaptic nerve terminal by choline acetyltransferase. Much of the choline 
needed for ACh synthesis is recycled following ACh hydrolysis, via a high affinity 
choline uptake transporter. Uptake of choline into the nerve terminal is the rate limiting 
step of ACh synthesis [26]. Following synthesis, ACh is concentrated into vesicles by the 
vesicular ACh transporter and an energy-dependent pump [27]. Vesicle exocytosis is 
triggered by calcium entry into the nerve terminal following the arrival of an action 
potential and opening of voltage-gated calcium channels. ACh released from the 
cholinergic neuron diffuses across the nerve synapse where it can stimulate postsynaptic 
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and, in some cases, presynaptic receptors. ACh binds and activates two classes of 
receptors, nicotinic and muscarinic, though it displays different affinities (KD ~ 30 nM for 
muscarinic and ~ 30 µM for nicotinic) [28]. The duration of activation resulting from 
ACh release is controlled by the enzyme acetylcholinesterase (AChE), which rapidly 
hydrolyzes unbound ACh molecules. AChE is one of the most efficient enzymes known, 
with a kcat/KM (108 x M-1 sec-1) which approaches the diffusion-controlled limit [29]. In 
fact, ACh degradation occurs on a faster time scale than the receptor activation cascade, 
preventing receptors from being activated more than once per release [25]. As a result, 
cholinergic receptor activation is rapid and sensitive, able to distinguish between 
sequential nerve impulses, a feature particularly important at the neuromuscular junction. 
Figure 2-1 summarizes the general features of a cholinergic synapse.  
Muscarinic acetylcholine receptors (mAChRs) are named after muscarine, a toxin 
produced by the mushroom Amanita muscaria which is an agonist at the aforementioned 
receptors [30]. MAChRs belong to the G protein-coupled receptor family, characterized 
by seven transmembrane regions and intracellular responses mediated by G proteins [30]. 
There are five subtypes of muscarinic receptors, M1 - M5, which differ in their sensitivity 
to pharmacological agents and participation in downstream functions. Odd numbered 
subtypes (M1, M3, M5) facilitate cell excitation through activation of phospholipase C, 
while even numbered subtypes (M2, M4) suppress cellular excitability through adenylyl 
cyclase inhibition and potassium channel activation [31]. In general, M1 receptors are 
concentrated in the central nervous system, M2 receptors are prominent in their 
modulation of cardiac function, M3 receptors are typically responsible for 
parasympathetic end organ responses, and all five receptor subtypes can be found in the 
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brain [32, 33]. However, much overlap occurs in the overall distribution of mAChR 
subtypes. 
Nicotinic acetylcholine receptors (nAChRs) were first identified for their 
sensitivity to the snake venom α-bungarotoxin, though they became known for their 
response to the agonist nicotine [34]. Unlike mAChRs, nAChRs are ligand-gated ion 
channels whose activation increases cation permeability (mainly Na+ and K+) to induce 
an excitatory reaction. A variety of nAChR subtypes exist as there are seventeen potential 
subunits (α1-10, β1-4, 𝛾, d, and 𝜀) and individual receptors are pentamers organized 
around a central pore. Receptors are often heteromeric containing both α and β subunits, 
but some homomeric receptors have been identified. Mature skeletal muscle contains 
primarily (α1)2β1d1𝜀1 nAChRs, while autonomic ganglia receptors frequently occur in a 
(α)2(β)3 configuration [35, 36]. Receptor subtypes found in the brain are formed from a 
variety of α/β combinations (e.g. (α4)2(β2)3, (α7)5, (α9)2(α10)3, etc.), and are often 
located presynaptically where they modulate the release of other neurotransmitters (e.g. 
glutamate or dopamine), though postsynaptic nAChRs also have functional importance 
[37-39]. 
Unsurprisingly, due to its pervasiveness, the cholinergic system has considerable 
medical relevance. In the peripheral nervous system, cholinesterase inhibitors have been 
used for the management of glaucoma and myasthenia gravis. In glaucoma, locally 
applied cholinesterase can facilitate movement of aqueous humor and decrease ocular 
pressure [40]. Myasthenia gravis, characterized by muscular weakness and fatigue, is 
typically caused by autoantibodies against nAChRs in the neuromuscular junction, 
resulting in reduced receptor density which can be countered with a cholinesterase 
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inhibitor [41]. In the central nervous system, certain neurodegenerative and 
neuropsychiatric conditions may be treated via cholinergic modulation. Alzheimer’s 
disease is characterized by the formation of β-amyloid plaques and neurofibrillary 
tangles, progressing to neuronal shrinkage and loss. Treatment with cholinesterase 
inhibitors (e.g. donepezil, rivastigmine) improves cognitive function in patients, though it 
does not slow disease progression [42, 43]. Tremors associated with Parkinson’s disease 
may also be improved by treatment with centrally-acting muscarinic antagonists [44]. 
More recently, it has been suggested that receptor agonists for (α7)5 nAChR and M1 and 
M4 mAChRs may be effective treatments for schizophrenia [45]. Other psychiatric 
conditions, including depression and bipolar disorder, may also be affected by 













Figure 2-1. Actions at the cholinergic synapse. Acetyl-CoA (A) and choline (Ch) are 
synthesized into acetylcholine (ACh) by the enzyme choline acetyltransferase (ChAT), 
and transported into release vesicles. Following release into the synapse, ACh binds to 
muscarinic and/or nicotinic acetylcholine receptors (mAChR & nAChR). 
Acetylcholinesterase (AChE) is present in the synapse to hydrolyze ACh, and choline 
generated from this reaction is taken into the pre-synaptic terminal by a high affinity 




Butyrylcholinesterase (BChE) is serine hydrolase that is closely related to 
acetylcholinesterase. It was first distinguished from AChE in the 1940s on the basis of 
substrate selectivity and distribution [47-49]. Originally, BChE was named 
pseudocholinesterase for its capacity to hydrolyze both choline and non-choline esters 
and its absence in brain tissue, which made it unlikely to function like the “true” 
cholinesterase, AChE [50]. 
Further research has refined the notion that BChE is not involved in cholinergic 
neurotransmission. While the highest levels of BChE are in the plasma and liver, it can in 
fact be found in the brain, skeletal muscle, and other cholinergic tissues [51, 52]. Studies 
in AChE knockout mice have shown that BChE can hydrolyze ACh in vivo, acting as a 
substitute for AChE, albeit a poor one [53]. Additionally, BChE knockout mice 
experience higher toxicity following exposure to the AChE-specific inhibitors donepezil 
and huperzine A [54]. These studies suggest that BChE may function to hydrolyze ACh 
in cholinergic synapses, under certain conditions.  
In addition to its role as a “backup” for AChE, BChE has long been implicated in 
the metabolism of ester drugs and toxicants. In the 1950’s it was recognized that the 
muscle relaxant succinylcholine (often used during anesthesia) caused prolonged apnea in 
some patients, an effect attributed to low plasma BChE activity [55]. BChE also plays a 
role in the metabolism of drugs such as aspirin (detoxification), cocaine (detoxification), 
and heroin (activation) [56-58]. The asthma prodrug bambuterol is converted by BChE 
into terbutaline [59]. BChE also interacts with organophosphorus toxicants similarly to 
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AChE [60]. This interaction is considered detoxifying, as BChE-bound OP compounds 
cannot thereafter interact with AChE.  
Recently, a role for BChE in ghrelin metabolism has also been examined. Ghrelin 
is a peripherally produced peptide hormone which is implicated in meal initiation, fat 
accumulation, rewarding/addictive behaviors and anxiety, among a host of other effects 
[61-63]. BChE converts active acyl-ghrelin to inactive desacyl-ghrelin, an effect seen 
both in vitro and in vivo [64-66]. Studies have shown that BChE knockout mice become 
obese on a high-fat diet due to an abnormal increase in adiposity, an effect that can be 
prevented by BChE gene transfer [66-68]. In contrast, mice given a cocaine-hydrolyzing 
variant of BChE weekly (1 mg/kg, iv) were shown to gain less weight on a high-fat diet 
as compared to controls [69]. Manipulation of BChE levels through gene transfer and 
genetic modification have also been shown to decrease aggressive behaviors in mice [70]. 
Further studies are necessary to elucidate the importance of BChE on ghrelin signaling. 
Such metabolic effects of BChE may have relevance, however, in its use as a 
prophylactic agent.  
Despite this array of functions, BChE activity is not considered essential. Mice 
completely lacking the BChE gene are indistinguishable from wild type mice under 
normal conditions [71]. This observation is also supported in humans. While mutations in 
AChE occur with low frequency, BChE mutations are relatively common. It is estimated 
that 35% of the American/European population has at least one mutated BChE allele, and 
the most frequent mutation, the K-variant, results in 33% reduced BChE activity [51, 72]. 
Furthermore, certain populations have been found with completely “silent” BChE 
activity. Studies of these individuals have revealed no abnormalities in regards to health, 
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fertility, and body weight [73]. Little is known, however, regarding how these individuals 
would react to challenges to cholinergic and ghrelin signaling pathways. 
2.1.1.1 BChE Structure and Mechanism 
The BChE monomer is a globular protein composed of 574 amino acids, nine N-
linked glycosyl groups, and three intra-chain disulfide bonds [74]. While these monomers 
are catalytically independent, BChE is primarily found in the tetrameric form. The BChE 
tetramer is considered a dimer of dimers; BChE dimers are formed though inter-chain 
disulfide bonds at Cys571, and these dimers assemble via non-covalent interactions at the 
C-terminus [75, 76]. C-terminal alpha helices form a superhelical structure surrounding a 
proline-rich peptide to yield the tetramer [77, 78]. The native tetramer has a molecular 
weight of 340 kDa, of which carbohydrates contribute 24% [79]. This unique structure 
contributes to the long plasma half-life of human BChE (~ 11 days) [80-82].    
The main structural feature of BChE is a ~20 Å long gorge protruding halfway 
into the protein, termed the “active site gorge” [83, 84]. Within this gorge there are 
several distinct regions which contribute to enzymatic function. Near its entrance, the 
peripheral anionic site (Asp70 and Tyr332) is responsible for initial binding of positively 
charged substrates (e.g. choline esters) [85, 86]. This site is also implicated in the non-
Michaelian behavior of BChE (i.e. substrate activation) [87]. Ester hydrolysis occurs near 
the bottom of this gorge via a catalytic triad (Ser198, Glu325, and His438) with 
assistance from a nearby oxyanion hole (Gly116, Gly117, and Ala199) [83]. Two 
additional sites near the catalytic triad, the acyl binding pocket (Leu286, Val288, and 
Trp231) and the choline binding site (Trp82; sometimes called π-cation site) aid in proper 
substrate orientation [83, 88]. While both AChE and BChE contain these domains, the 
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volume of BChE’s gorge is 200 Å larger than AChE due to fewer aromatic amino acids 
[89]. This space disparity is the basis for substrate/inhibitor selectivity, as the AChE 
gorge is too small to accommodate larger molecules (e.g. butyrylcholine, succinylcholine, 
ethopropazine, iso-OMPA) [90].  
Substrate catalysis by BChE and AChE is carried out with an active site triad via 
an Ordered Uni Bi reaction mechanism (i.e. one substrate, two products). Mutations in 
these residues can produce an incorrectly folded enzyme with no enzyme activity [91]. 
During acylation, Ser198 carries out a nucleophilic attack on the carbonyl carbon, aided 
by a general acid-base catalytic element provided by the imidazole ring on His438. A 
tetrahedral intermediate is formed as a result of this attack. Proton transfer from the 
imidazole ion on His438 initiates the expulsion of a leaving group (product 1; e.g. 
choline) leading to the formation of the acylated enzyme [59]. The deacylation step 
begins with a nucleophilic attack by water, and results in the regenerated enzyme and 
product 2 (e.g. butyric acid) [92]. In the case of phosphylated adducts, altered 
stereochemistry results in impaired general base function of His438 during the 
dephosphylation step (i.e. reactivation) and consequently inhibited function [93, 94]. The 
last member of the catalytic triad, Glu325, does not directly participate in catalysis, but 
instead stabilizes the tetrahedral intermediates and transition states via electrostatic 
interactions [95]. The oxyanion hole serves a similar role, as its NH peptidic backbone 
stabilizes the partial negative charge which develops on the carbonyl oxygen [92, 95, 96]. 
Knowledge of BChE’s structure and mechanism at a molecular level has enabled both 
past and present enzyme mutagenesis studies aimed at improving catalysis of certain 




OP compounds have a wide range of uses and applications.  Due to their potent 
anticholinesterase activity, they have been used for over half a century as insecticides in 
agricultural, residential and commercial settings worldwide. In 2012, 20 million pounds 
of OP insecticides (accounting for 33% of U.S. insecticide market) were applied on 
cotton, fruit, vegetable, and orchard grape crops, among others [97]. Their market share 
in low-income and developing nations is even higher [98]. OP compounds can also be 
used as flame retardants, plasticizers, and lubricants, useful for industry and as additives 
in a number of household products [99, 100].  
Unfortunately, these compounds were quickly recognized for their potential to be 
used for nefarious purposes. During a search for better insecticides in the mid-1930s, the 
German chemist Gerhard Schrader developed a highly potent organophosphorus 
compound he named tabun (ethyl dimethylamidocyanophosphate; GA) [101]. While it 
was too toxic to be used as an insecticide, the Nazi government took interest in the 
chemical as a potential warfare agent in the looming World War. By the end of the war, 
Germany had stockpiled between 10,000-30,000 tons of tabun, and German scientists had 
developed more OP warfare agents including sarin (isopropyl 
methylphosphonofluoridate; GB) and soman (pinacolyl methylphosphonofluoridate; GD) 
[5]. This class of ultra-potent OPs became known as “nerve agents” which grew to 
include cyclosarin (O-cyclohexyl methylphosphonofluoridate; GF), VX (S-(2-
diisopropylaminoethyl) O-ethylmethylphosphonothiolate), and others in the proceeding 
decades. VX is considered the most potent nerve agent with a LCt50 of 10 mg(min)/m3, 
which is 500-times that of cyanide [5]. 
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While nerve agents were never deployed in WWII, they have been used in other 
military conflicts such as the Iraq-Iran Civil War (1980s) and the Syrian Civil War 
(2013), killing thousands [2, 102-104]. Sarin was used by Aum Shinrikyo, a Japanese 
terrorist group, to carry out attacks in Matsumoto, Japan (1994) and the Tokyo Subway 
(1995), which together claimed the lives of 19 individuals and hospitalized hundreds [5]. 
In 2017, the former heir apparent to North Korea, Kim Jong Nam, was murdered at a 
Malaysian airport using VX [3]. Most recently, a nerve agent was used in the attempted 
murder of former Russian spy Sergei Skripal and his daughter in England [4]. In the case 
of the Skripals, it has been reported that a Russian “Novichok” agent was used in the 
attack. Little is known about Novichok agents as they remain classified, but it is thought 
that they are even more potent than VX [105]. 
In 1997 a multinational treaty regarding chemical weapon use, called the 
Chemical Weapons Convention, was enacted. Signatory nations agreed to cease 
production of chemical weapons and destroy current chemical stockpiles. Originally there 
were 165 signatory states, and in subsequent years 28 additional states have acceded to 
the treaty [106]. Syria acceded to the treaty following international pressure as a result of 
the 2013 nerve agent attack. Subsequently, the OPCW (the governing body for the treaty) 
established a program to destroy Syria’s remaining chemical weapons [107]. The OPCW 
estimates that 97% of declared chemical weapons have been destroyed [108]. As of 2019, 
however, three states have not acceded to the treaty: Egypt, North Korea, and South 
Sudan. Additionally, while Israel was one of the original signatory states, it has never 
ratified the treaty. Concern remains, though,  that some signatory nations may have 
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undeclared chemical weapons [109]. Moreover, possession of chemical weapons by 
violent non-state actors cannot be ruled out, as evidenced by the attacks in Japan. 
2.2.1 Chemical Properties of OP Compounds 
Most OPs are derivatives of phosphoric, phosphonic, or phosphinic acid, 
containing a characteristic phosphorus-oxygen double bond. OP insecticides are often 
organophosphorothioates which contain a P=S group in place of P=O. These compounds 
must be metabolically activated (via oxidative desulfuration) to the “oxon” form (P=O) 
prior to exerting potent anticholinesterase activity [110]. In contrast, nerve agents do not 
require metabolic activation to exert toxicity. 
OP insecticides are generally lipophilic with low volatility [111]. While these 
characteristics are desirable for agricultural use, exposure to highly lipophilic OP 
compounds may result in fatty tissue distribution and prolonged toxicity. In general, 
nerve agents have relatively lower lipophilicity, in most cases higher volatility (especially 
sarin), and higher vapor density [112]. These characteristics make aerosol formulations of 
nerve agents particularly hazardous (other than VX, which is primarily a contact hazard). 
Moreover, nerve agents are colorless and odorless which, combined with their high 
toxicity, make them an insidious threat [112].  
2.2.2 Kinetic Scheme of Cholinesterase Inhibition 
The reaction of cholinesterases (ChEs) with OP compounds follows the general 
outline shown in Figure 2-2. An important distinction between the two lies in the 
deacylation/dephosphylation step. While acylated enzymes rapidly deacylate via 
hydrolysis to regenerate the free enzyme, phosphylated enzymes do not. Because of this, 
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OP compounds are generally considered irreversible inhibitors; spontaneous reactivation 
of ChEs may occur slowly in humans (hours to days), though not at a clinically relevant 
rate [113-115]. In some cases, the phosphylated enzyme undergoes a further dealkylation 
reaction, termed aging, which results in a truly irreversibly inhibited enzyme [116]. 
Common nerve agents have an in vitro aging half-time between three minutes (soman) 












Figure 2-2 Interaction of OP compounds and AChE. First, the OP compound and  AChE 
form a reversible Michaelis-complex (k1/k-1), however, the bond quickly progresses 
through this step and is phosphorylated (k2). Following phosphorylation, the compound 
may go through two different pathways. The OP can reactivate, either spontaneously or 
through the use of nucleophilic agents (e.g. oximes, fluoride salts) at a rate of k3. Some 
agents go through a dealkylation reaction prior to the k3 step, resulting in an aged 








2.2.3 Toxicity from OP Compounds 
Though nerve agent exposure is the focus of much research, including herein, 
most acute OP compound exposures are the result of intentional insecticide poisonings. 
Recent data suggest that pesticide self-poisoning causes 170,000 deaths annually, 
accounting for about 20% of global suicides [119]. Prospective studies on hospitalized 
self-poisoning patients demonstrated that OP compounds were the most commonly used 
pesticide class (~30-60%), though increased regulations on them seem to be decreasing 
their prevalence over time [120-122]. Overall lethality associated with OP ingestion is 
around 10% for treated individuals, though it varies greatly based on the specific 
compound and formulation and can be up to 60% [120-123]. The variability in mortality 
following OP insecticide exposure is confounded by many variables including delays in 
treatment and treatment mismanagement.  
While acute toxicity from OP compounds works primarily though inhibition of 
AChE, interestingly, there is some evidence that suggests differential toxicity of certain 
organophosphates could be due to effects on secondary targets, including acetylcholine 
synthesis, direct binding to receptors, and others [124]. Furthermore, some OPs inhibit 
other hydrolases including carboxylesterase, fatty acid amide hydrolase, and 
monoacylglycerol lipase [125]. As a result, the following discussion describes the typical 
effects of acute exposure to OP compounds. However, unique effects of certain 
organophosphates should not be ignored. For example, some OP compounds (e.g. tri-o-
cresyl phosphate, leptophos, mipafox) cause delayed neurotoxicity as a result of 
secondary interactions with the enzyme neurotoxic esterase [126]. Further discussion of 
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the toxicological relevance of secondary targets of OP compounds is contained in the 
cited reviews [60, 127-129].  
The general toxidrome resulting from overstimulation of the peripheral nervous 
system by OP compounds includes a variety of signs and symptoms. In the 
parasympathetic system, inappropriate stimulation of secretory glands induces salivation, 
rhinorrhea, bronchorrhea and lacrimation, while overstimulation at smooth muscle 
receptors results in miosis, bronchospasm, diarrhea, nausea/vomiting, and urinary 
incontinence. Though parasympathetic effects generally predominate, signs arising from 
sympathetic overstimulation also occur. Recall that eccrine sweat glands are the only 
sympathetic endpoint with postganglionic cholinergic neurons. As a result, excessive 
sweating (i.e. diaphoresis) is present in about one in four patients seen for toxicant 
ingestion [130, 131]. Cardiovascular effects may present as sympathetically or 
parasympathetically driven. In six studies of humans exposed to OP insecticides (354 
patients between 1974 - 2010), an abnormal heart rate was detected in 48% of patients on 
admission, with 72% of those affected presenting with tachycardia [130-135]. 
Furthermore, patients with abnormal blood pressure (23%) were more often hypertensive 
(66%). These effects may arise due to increased activity in the autonomic ganglia acting 
to increase postganglionic adrenergic activation or adrenal stimulation and subsequent 
catecholamine release. It could also reflect overstimulation and failure of cholinergic 
signaling such that vagal input is overall reduced, leading to relative sympathetic 
overstimulation. Signs resulting from prolonged stimulation at the neuromuscular 
junction include fasciculations, weakness and flaccid paralysis, usually presenting in 
more severely intoxicated individuals. Victims determined to have moderate to severe 
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poisoning from the Tokyo Subway attack frequently presented with fasciculations (25%) 
and muscle weakness (35%) [136]. 
In the central nervous system, cholinergic overstimulation causes tremors, ataxia, 
respiratory depression, seizures, and coma. These effects generally only occur in severe 
intoxications, with respiratory failure being the most common cause of death [137]. Loss 
of central respiratory drive appears to be the predominant factor in organophosphate-
induced respiratory failure, though peripheral effects contribute (e.g. bronchorrhea, 
bronchospasm, diaphragm contraction, etc.) [138, 139]. This effect is likely mitigated by 
mAChRs, supported by findings that centrally-acting muscarinic antagonists (e.g. 
atropine) mitigate respiratory effects, while peripheral muscarinic antagonists (e.g. 
methylatropine, glycopyrrolate) do not [140, 141]. Similar studies have also suggested 
mAChRs are the primary receptor type involved in organophosphate-induced seizures 
[142]. Though seizure initiation seemingly results from mAChR overstimulation, a three-
phase model of seizure progression has been proposed, wherein other neurotransmitter 
systems (e.g. glutamatergic) are recruited [143]. 
Clinical presentation of anticholinesterase toxicity is dependent on many factors, 
including the molecular structure of the OP molecule, absorbed dose and route of 
exposure [144]. In the case of OP nerve agents, exposure is most likely to occur through 
the dermal and inhalation routes. Following a dermal exposure, symptom onset is delayed 
and will initially present as diaphoresis and fasciculations at the site of exposure. In 
moderate poisonings, toxicity will progress to systemic parasympathetic symptoms [5]. In 
contrast, inhalation of vapors or aerosols results in rapid onset of toxicity, peaking only 
minutes after exposure [145]. Miosis is the most sensitive endpoint during mild vapor 
 
 24 
exposures followed by mild wheezing and difficulty breathing. Moderate exposures will 
become systemic, with respiratory and ocular signs becoming more pronounced [5]. Data 
collected during the Tokyo Subway attack (inhalation of sarin vapor) showed that miosis, 
headache, dyspnea, nausea and eye pain were most commonly experienced in 
hospitalized victims, which supports the previous notion [136]. The same study found 
that in severely intoxicated individuals (n=4) recovery of red blood cell AChE activity 
into the normal range took approximately two months.  
2.2.4 Post-Exposure Treatment 
Management of OP intoxication involves several therapies aimed at different 
aspects of the toxidrome. A centrally-acting muscarinic receptor antagonist, usually 
atropine, is given to suppress muscarinic effects in the parasympathetic and central 
nervous systems [146]. Other mAChR antagonists including glycopyrrolate and 
scopolamine have been studied with some success, though the recommendation for 
atropine is unlikely to be revised [147, 148]. Conversely, effects at the neuromuscular 
junction (i.e. fasciculations, paralysis) are managed indirectly via intubation/mechanical 
ventilation and oximes [5, 149]. Some researchers have suggested that pharmacological 
intervention at nAChRs may be beneficial, though a recent clinical trial of rocuronium (a 
nAChR antagonist) failed to find beneficial outcomes with its use [150, 151].  
Oximes (e.g., pralidoxime, obidoxime) are strong nucleophiles which can 
reactivate phosphylated AChE, restoring catalytic activity and thus decreasing the 
accumulation of acetylcholine in cholinergic synapses [152]. Unfortunately, aging of the 
OP-enzyme adduct renders oximes ineffective so the value of this treatment is highly 
dependent on the identity of the OP compound and the timing of oxime administration. 
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Because of this, the practical benefit of oxime administration is debated. Meta-analyses 
and clinical studies on patient outcomes following oxime treatment have not come to a 
shared conclusion, with some suggesting that it is beneficial while others find no benefit 
[153-156]. A reactivating agent that is effective on aged OP-AChE adducts may solve 
this issue, though development of such an agent is mechanistically difficult, and attempts 
have not yet been successful [157-159].  
While atropine and oximes are the principal treatments, other management 
strategies may also be employed when appropriate. Benzodiazepines (e.g. diazepam and 
midazolam) are used to suppress seizure activity [160]. As severe toxicity may result in 
loss of consciousness and/or flaccid paralysis, seizure activity may be difficult to 
recognize. Thus, it is appropriate to administer anticonvulsants until the absence of 
seizure activity can be confirmed. Gastrointestinal decontamination (i.e. lavage or 
charcoal administration) is sometimes performed following OP ingestion, though the 
benefit of such treatments is dubious due to the rapid absorption of the toxicant from the 
stomach [161, 162]. Alternatively, in cases of percutaneous or vapor exposure, skin 
decontamination (i.e. clothing removal and alkaline rinse) may be important to halt 
further chemical absorption as well as prevent secondary exposures.  
In addition to those discussed above, a variety of adjunctive treatments have 
demonstrated positive effects in laboratory studies, though they have little, if any, clinical 
evidence. Administration of glutamate receptor antagonists (e.g. gacyclidine, 
caramiphen) aid in seizure attenuation, improving survival and recovery when given up 
to 45 minutes after intoxication and standard antidotes [163-166]. The anti-epileptic drug 
levetiracetam has also been shown to further enhance anti-seizure effects when given in 
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conjunction with anticholinergic and antiglutamatergic drugs [167]. Another study found 
that a combination of procyclidine and propofol are also able to terminate seizures long 
after onset, though this regimen could not be administered outside of a hospital setting 
[168]. Brief isoflurane administration may also have neuroprotective effects when given 
between 20-30 minutes following exposure [169]. Nebulized ipratropium bromide, a 
medication commonly used in COPD, has also been used to counteract bronchospasm 
[170]. 
2.2.5 Sequalae of OP Toxicity 
Even with successful treatment, exposure to OP compounds can result in a wide 
variety of persistent neurological consequences [171]. Seizures resulting from OP 
intoxication can induce extensive neuronal damage, including cell death [172]. However, 
there is evidence that neuropathological changes may occur even when seizures are 
prevented or rapidly terminated [173-176]. Neuropathological changes following OP 
toxicity have been correlated with persistent behavioral deficits in animal models [177-
181].  
While neuropathology cannot currently be determined in humans, 
neurobehavioral and neurophysiological effects of OP toxicity have been studied. One 
year after the Tokyo Subway attack, exposed individuals showed a decrease in event-
related potential and visual-evoked potentials, which reflect cognitive and visuomotor 
function respectively [182, 183]. In another study, victims reported continued ocular 
symptoms (18.5%), fatigue (12%) and headache (8.6%), among other symptoms one-year 
post-exposure [184]. In a seven-year follow-up, exposed individuals had significantly 
decreased performance on tests of psychomotor function (finger tapping test) and 
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working memory (backward digit span test) compared to the reference population [185]. 
Pesticide applicators may also be unintentionally exposed to OP compounds [186-188]. 
Compared to non-farmworkers, these populations showed decreased scores on a variety 
of cognitive and neurobehavioral tests (verbal abstraction, visuomotor speed, memory, 
attention) [189-193]. These studies show that there continues to be a need for developing 
effective strategies to prevent and treat OP compound intoxication. 
2.3 PRE-EXPOSURE PROPHYLAXIS 
2.3.1 Carbamates 
While post-exposure therapy is the only option for civilians involved in an 
unexpected attack, militaries employ carbamates for prophylaxis against nerve agent 
threats. Carbamates are a class of chemicals that bind to and inhibit AChE, but with much 
shorter duration than OP compounds. It was first reported in 1946 that administration of 
the carbamate physostigmine protected animals against the toxic effects of the 
organophosphate DFP [194]. Superficially, it seems illogical that protection against OP 
anticholinesterases can be achieved by preadministration of another anticholinesterase. 
The mechanism of carbamate pretreatment is two-fold. First, carbamates transiently 
occupy the AChE active site thereby preventing binding by a more persistent OP 
inhibitor. Second, over the course of an exposure, carbamylated enzymes spontaneously 
reactivate (half-life of 15-30 minutes in vitro) [195]. This provides a steady source of 
catalytically active AChE, consequently reducing the effects of OP toxicity. It is 
important to note, however, that the efficacy of carbamate pretreatment is dependent on 
receiving the standard post-exposure therapy following exposure. When animals are 
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exposed to OP inhibitors but not given the standard antidotes, carbamate pretreatment 
does not influence the toxic outcome [196-198].  
Pyridostigmine bromide (PB) is the most commonly used carbamate for nerve 
agent prophylaxis. The U.S. military first utilized PB as a prophylactic agent during the 
Persian Gulf War (1990-1991), and it remains the only FDA-approved carbamate 
pretreatment. In rhesus monkeys exposed to soman, PB pretreatment demonstrated a 
protective ratio (PR; factor by which the LD50 of untreated group is increased) of greater 
than 40 when used in conjunction with standard antidotes. For comparison, the standard 
therapy alone had a PR of 1.6 [16]. When pre-exposure PB is given in addition to the 
standard antidotes against tabun, the PR is increased from 4.4 to 12.1 (in guinea pigs) and 
1.3 to 2.1 (in mice) [199]. While the inclusion of PB is beneficial with soman and tabun 
exposures, PB does not increase the PR against sarin and VX exposures [16, 199]. The 
efficacy of standard antidotes with sarin (PR=34.6) and VX (PR=58.8) is much better 
than with soman and tabun, which may contribute to the relative lack of effect of PB 
[199]. The presence of PB, however, has been shown to have no or minimal effect on 
survivability of guinea pigs following exposure to sarin or VX [200].  
Ideally, peripheral AChE activity including AChE in blood should be inhibited 
20-40% by the carbamate pretreatment [16]. While higher occupation of AChE sites 
would theoretically make the pretreatment more effective, it could also lead to increased 
anticholinesterase toxicity. It should be noted that the efficacy of PB prophylaxis is solely 
due to the protection of AChE in the peripheral nervous system, as PB does not readily 
cross the blood-brain-barrier due to the presence of a quaternary nitrogen in its structure. 
In military settings, PB is administered as 30 mg tablets taken every 8 hours to achieve 
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this outcome. The oral bioavailability of PB in humans is low (around 10-15%). The time 
to peak plasma concentrations of PB is about 2 hours (though this can be significantly 
increased if taken with food), and the elimination half-life of PB from plasma is 100-200 
minutes [201, 202]. AChE levels return to normal activity 10 to 12 hours following the 
last dose of 30 mg PB tablets [203].  
Soldiers taking PB have reported acute side effects including gastrointestinal 
distress (50%), urinary urgency (5-30%) and headache (<5%) [204]. Pyridostigmine was 
originally implicated in contributing to Gulf War Illnesses [205], however recent research 
suggests the pathogenesis is multifactorial, with PB only being a possible contributing 
factor [206]. Due to the incomplete efficacy, non-ideal pharmacokinetics, and potential 
side effects of PB administration, further research into prophylactic treatments based on 
PB is warranted.  
In addition to PB, several other reversible AChE inhibitors have been investigated 
as prophylactics. As noted above, physostigmine is a centrally-acting carbamate which 
has been shown to provide increased protection against DFP, soman, and sarin in 
comparison to PB [197, 207, 208]. Despite this, the in vivo pharmacokinetics of 
physostigmine (half-life of 30 minutes) pose a significant barrier to practical use [209]. 
Several centrally-acting reversible AChE inhibitors used in treating dementia and 
Alzheimer’s disease — rivastigmine, donepezil, huperzine A, and galantamine — have 
also been investigated for their prophylactic capability [210]. Rivastigmine was tested in 
human volunteers and determined to have limited use as a prophylactic due to non-linear 
pharmacokinetics, high inter-subject variability, and cognitive function decrements [211]. 
Galantamine provides marked protection against paraoxon, sarin, and soman treated 
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guinea pigs, particularly when combined with atropine post-treatment [212]. It has also 
been shown to prevent soman-induced brain damage in guinea pigs [213]. Centrally-
acting cholinesterase inhibitors, however, are likely to induce behavioral side effects 
[214]. Physostigmine has been shown to alter behaviors such as startle reflexes and 
prepulse inhibition [215]. Furthermore, physostigmine, galantamine, huperzine, and 
donepezil significantly depress locomotor activity in rats [216]. While these 
investigational drugs may have improved efficacy compared to PB, issues with 
tolerability have not been definitively solved. 
2.3.2 Bioscavengers 
Bioscavengers are proteins which can bind to and inactivate toxicants in the 
circulation before they can distribute into target tissues. This approach was first 
attempted in 1987 by Wolfe and colleagues, who found that pre-administered AChE was 
able to prevent lethality in rodents exposed to 3.5 LD50s of VX [217]. AChE acts as a 
stoichiometric scavenger, as a ratio of two moles of AChE to one mole of VX was 
necessary to maintain protection.  In 1991, Broomfield and colleagues showed that BChE 
was an effective prophylactic in rhesus monkeys, blocking cholinergic signs of toxicity 
and behavioral changes following OP challenge [218]. These initial studies spurred 
further interest in the development of a suitable bioscavenger for protection against OP 
intoxication.   
Both AChE and BChE bind stoichiometrically to OP anticholinesterases. The so-
called “second-generation” bioscavengers catalytically hydrolyze OP molecules; 
therefore, they are theoretically capable of protecting individuals against higher OP 
exposure levels while requiring lower doses of the enzyme. The first in vivo study 
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utilizing a catalytic scavenger, a bacterial parathion hydrolase, was conducted by Ashani 
and colleagues [219]. Administration of a small amount of this bacterial enzyme was able 
to increase the LD50 of paraoxon 3-fold in rodents. Further studies on catalytic scavengers 
have focused on bacterial phosphotriesterases and human paraoxonase, among others 
[220].  
Several characteristics have been set forth which describe an ideal enzyme-based 
prophylactic (i.e. bioscavenger) [221]. First, the molecule must react rapidly and 
efficiently against a broad spectrum of OP molecules. Preferably, a bioscavenger should 
inactivate enough OP molecules to render a non-toxic dose within one median circulation 
time (~ 1 minute) to prevent all effects of OP toxicity [222]. Second, the scavenger must 
be biologically compatible (i.e. no toxic effects and lack of immunoreactivity) with a 
long in vivo half-life. Lastly, the scavenger should be suitable for large-scale industrial 
production, being inexpensive to produce and possessing a long shelf-life. 
2.3.2.1 Stoichiometric 
While acetylcholinesterase was the first studied enzyme bioscavenger, it has not 
been the primary focus of further research. This could be due to the lack of a suitable 
source of purified human AChE [88]. Therefore, studies on this enzyme have utilized 
sources such as fetal bovine serum AChE or recombinant human AChE (rhAChE). While 
these enzymes are effective against several nerve agents (VX, soman, sarin), their non-
native source poses potential immunogenicity issues and a short in vivo half-life 
(particularly with rhAChE) [217, 221, 223-225]. It is interesting to note, however, that 
AChE has better stereoselectivity for the more toxic OP enantiomers as compared to 
BChE [223].  
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Carboxylesterase (CarbE) is an enzyme found in plasma and other tissues which 
is highly sensitive to inhibition by a number of OP compounds [226]. Inhibition of 
endogenous plasma CarbE activity decreases the LD50 of soman, indicating that the 
sequestration of OP molecules by carboxylesterase is an endogenous scavenger for 
modulating toxicity [227]. This is supported by the notion that species with high levels of 
CarbE are more resistant to OP toxicity [228]. CarbE is generally considered a broad-
spectrum enzyme; however, the rate at which it reacts with some OP compounds is poor. 
While CarbE reacts at a similar rate to AChE and BChE with paraoxon, sarin, soman and 
DFP, it exhibits significantly slower reactivity with echothiophate and VX [229]. This 
observation lessens CarbE’s utility as a broad spectrum bioscavenger. At present, it is 
unknown how CarbE would perform as an exogenously injected bioscavenger.  
Butyrylcholinesterase is the most well-studied of the potential enzyme-based 
prophylactics [88]. Prophylactic administration of BChE can provide protection against 
subcutaneous soman (5.5 x LD50) and VX (8 x LD50), without the standard antidotes 
[230, 231]. This strategy is also effective following dermal (VX) and inhalation 
exposures (soman and sarin) [232-234]. Pretreatment with BChE not only prevents 
lethality, but it prevents nonlethal neurological and behavioral deficits resulting from an 
OP exposure [235, 236]. Furthermore, several studies have demonstrated the safety of 
administration of large amounts of BChE. Animals receiving human BChE (60 mg/kg; 
im or ip) exhibit no clinical signs of toxicity, have physiologically normal serum 
chemistry and hematological profiles, and lack histopathological changes post-mortem 
[231]. BChE administration also does not alter behavioral endpoints such as acoustic 
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startle reflexes and prepulse inhibition [215], attention, short-term memory [237], 
avoidance learning, motor activity or schedule-controlled behavior [236, 238].  
2.3.2.2 Catalytic 
Since OP compounds are hemi-substrates of BChE, it is conceivable that an OP-
hydrolyzing BChE mutant could be rationally designed.  Over three decades ago it was 
hypothesized that introduction of another nucleophile near the active site may facilitate 
hydrolysis of OP compounds [239]. Subsequent evaluation of a series of single point 
mutations in the oxyanion hole of BChE to histidine found one mutant (BChEG117H) with 
a marked increase in paraoxon, echothiophate, sarin, and VX hydrolysis [14, 240]. 
Despite these in vitro improvements, BChEG117H was decidedly less protective than 
recombinant BChE in vivo against sarin, soman, or VX [241]. Since the characterization 
of BChEG117H, over 60 different BChE mutants have been used to test the effects of 
alternating histidine positions, changing amino acids at the 117 position, adding positive 
charges in BChEG117H, and introducing negative charges to increase the nucleophilicity of 
histidine, among others [242]. To date, no other mutants have shown significant 
improvements in organophosphate hydrolysis compared to BChEG117H.  
Other human enzymes which possess catalytic activity towards OP compounds 
are of considerable interest. Paraoxonase-1 (PON1) is a plasma enzyme associated with 
high-density lipoproteins which has a variety of functions, including organophosphate 
hydrolysis [243]. PON1 efficiently hydrolyzes several OP compounds, including G-type 
nerve agents [244, 245]. While PON1 does not function at the ideal kcat/KM (>107 M-1 
min-1), it only needs to be improved by one to two orders of magnitude to reach this goal 
[246]. In mice, recombinant PON1 (10 mg/kg) was able to protect against 4 x LD50 of 
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chlorpyrifos oxon, but not 2 x LD50 of any G-type nerve agents [247]. In another study, 
however, 5U of human PON1 partially protected rodents against inhalation exposure to 
sarin and soman (1.2 x LCt50) [248]. The incomplete protection afforded by wild-type 
PON1 may be due to its propensity to bind to the less toxic nerve agent enantiomers 
[249]. Directed evolution of human PON1 produced a mutant (IIG1) with 40- to 3,400-
fold increased efficiency at hydrolyzing the toxic enantiomers of sarin, soman, and 
cyclosarin [250]. IIG1 also acquired the ability to slowly hydrolyze VX, though not 
efficiently enough to be useful in vivo. IIG1 was able to protect against 2 x LD50 of 
cyclosarin at low levels (1 mg/kg, iv) [251]. Large-scale implementation of PON1, 
however, faces production, stability and pharmacokinetic challenges [252]. Other human 
enzymes such as liver prolidase and senescence marker protein 30 have been suggested 
as potential candidates of interest, though data are sparse on their efficacy [253-255].  
Bacterial phosphotriesterases (PTE) are the most active and broad-spectrum OP 
hydrolyzing enzymes; however, they face difficulties translating to human use due to 
issues with immunogenicity, making structural modifications necessary [256]. The PTE 
from Brevundimonas diminuta (formerly Pseudomonas diminuta), commonly called 
organophosphorus hydrolase (OPH), efficiently hydrolyzes both G-type and V-type nerve 
agents [257-259]. The wild-type enzyme was shown to protect rodents against multiple 
LD50s of paraoxon, an analog of DFP, sarin, and tabun [207, 219, 260]. Furthermore, 
mutagenesis studies have been relatively successful in further increasing the catalytic 
efficiency of OPH [261, 262]. Evaluation of an evolved OPH mutant showed that a 5 
mg/kg dose was able to protect against two-times the LD50 of VX, even when given post-
exposure [263, 264]. Phosphotriesterases from other bacterial sources including 
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Sulfolobus solfataricus, Agrobacterium radiobacter, and Pseudomonas 
pseudoalcaligenes have also been tested with some success [265-267]. Overall, more 













CHARACTERIZATION OF THE RELATIVE IN VITRO ENZYME ACTIVITY, 
INHIBITOR INTERACTION, OP BIOSCAVENGING CAPACITY, AND STABILITY 
OF FREE AND COPOLYMER-COMPLEXED BCHE 
 
3.1 INTRODUCTION 
Though BChE is an effective bioscavenger, large scale production of human serum 
BChE (huBChE) is not economically feasible. A dose of 200 mg of huBChE is predicted 
to protect a 70 kg individual from 2 x LD50 of VX, soman, and sarin [268]. Using this 
estimate it is predicted that the US could produce around 5,000 doses annually by 
dedicating the entire supply of outdated plasma for BChE purification [241]. In contrast, 
recombinant human BChE (rhBChE) can be produced in large amounts using systems 
including CHO cells [269], insect cells [270], in transgenic goat’s milk [271], and 
tobacco leaves [241]. Recombinant enzymes, however, pose additional challenges 
including a reduced circulatory time and reduced stability resulting from altered 
oligomerization and glycosylation [51, 81].  In mice, human serum BChE has a
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half-life of 18 hours in the circulation while tetrameric rhBChE has a half-life of only 6 
hours [272]. Monomeric rhBChE has an even shorter circulatory time, with a half-life of 
2 minutes [273]. A similar trend would be expected with administration in humans.  
Structural modification of rhBChE may improve its pharmacokinetic characteristics. 
For example, poly(ethylene glycol) (PEG) is a long amphiphilic molecule which can be 
attached to therapeutic proteins and enzymes to limit their clearance from the circulation. 
PEG conjugation can improve solubility and stability, as well as extend in vivo half-life 
by protecting against proteolytic degradation, reducing renal clearance and masking 
antigenic epitopes [11]. This is due, in part, to the increased size of PEG-conjugated 
proteins. Each ethylene glycol molecule associates with 2-3 water molecules, increasing 
the molecular volume to weight ratio and creating a steric barrier to prevent proteolytic 
and immunogenic interactions [274]. Direct PEGylation has been previously shown to 
extend the half-life of rhBChE in mice [271, 272]  
Gaydess and colleagues reported a poly-L-lysine (PLL) copolymer grafted with PEG 
(PLL-g-PEG), which is able to ionically associate and form a stable complex with BChE. 
These copolymer complexes aided in the delivery of tetrameric BChE into the brain [9]. 
The ability of a copolymer carrier to alter pharmacokinetic properties of BChE may make 
it potentially useful as a bioscavenger. Furthermore, this copolymer formulation readily 
allows for conjugation of targeting ligands. Ligands such as the small peptide ERY1 or 
the monoclonal antibody TER119 may allow selective binding of copolymer-complexed 
BChE to circulating erythrocytes, which could lead to pharmacokinetic improvements 
significantly beyond the effect of PEG alone [275].   
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Despite the potential pharmacokinetic improvements, the copolymers’ effect on 
pharmacodynamics cannot be ignored. Bioscavengers must react rapidly with toxicants 
and be stable in vitro and in vivo [276], and enzyme modification via copolymer 
complexation may alter characteristics important for this goal (e.g., binding affinity, 
catalytic rate). While the effect of direct PEG conjugation of BChE on catalytic activity, 
proteolytic sensitivity, and thermostability has been previously investigated [272, 277], 
the effect BChE complex formation with a PLL-g-PEG copolymer on catalytic and 
scavenging properties has not been previously studied.  
The major goal of Aim 1 was to evaluate enzyme characteristics in copolymer 
complexes related to catalytic activity and bioscavenging capacity. We hypothesized that 
PLL-g-PEG complexes with BChE would have little effect on esterase activity or binding 
to OPs, while enhancing stability.  First, we estimated the kinetic parameters for substrate 
hydrolysis (Vmax, KM) for free (i.e., BChE treated in the same manner as enzyme 
undergoing copolymer complexation except that no copolymer is added) and the 
copolymer-complexed enzyme. We systematically characterized BChE-copolymer 
complexes using different sizes of copolymer (low [4-15 kDa], medium [15-30 kDa], 
high [30-70 kDa]) to study potential changes in interactions with substrates and 
inhibitors. We also evaluated the effect of copolymer complexation on enzyme-inhibitor 
kinetics with four selected OP inhibitors (paraoxon, DFP, echothiophate, and 
pyridostigmine) by comparing the bimolecular rate constant (ki) obtained with each 
inhibitor. These studies provided insight into effects that the copolymer may have on the 
enzyme’s catalytic capacity and potential to bind to and inactivate OP molecules. We also 
examined the effect of copolymer complexation on enzyme stability in vitro to both heat 
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and proteolytic enzymes (chymotrypsin, trypsin, and pronase). These studies provided 
insight into how the PLL-g-PEG copolymer may influence the stability of the complexed 
enzyme, both in the circulation and with storage. 
3.2 MATERIALS AND METHODS 
3.2.1 Chemicals 
 Recombinant human butyrylcholinesterase was produced by Dr. Liyi Geng (Mayo 
Clinic; Rochester, MN) as described in Pope and colleagues [10]. Paraoxon (O,O’-
diethyl-p-nitrophenyl phosphate; PO) (98.6% purity by HPLC) was purchased from 
ChemService (West Chester, PA). A 10 mM stock solution of paraoxon was prepared in 
100% dry ethanol and kept desiccated under nitrogen at -80°C until use. 
Diisopropylfluorophosphate (2-[fluoro(propan-2-yloxy)phosphoryl]oxypropane; DFP) 
(99% purity by NMR) was kindly provided by Dr. Derik Heiss at Battelle Memorial 
Institute (Columbus, OH) and stored as provided at -80°C [278]. Echothiophate iodide 
(2-diethoxyphosphorylsulfanylethyl(trimethyl)azanium; EthP) was originally obtained 
from Wyeth-Ayerst and was a kind gift from Dr. Oksana Lockridge (University of 
Nebraska, Omaha, NE). Pyridostigmine bromide (3-(dimethylaminocarbonyloxy)-1-
methylpyridinium bromine; PB) (100% purity by HPLC) was purchased from Sigma-
Aldrich (St. Louis, MO) and kept desiccated under nitrogen at room temperature until 
use. Chymotrypsin (Type II from bovine pancreas; ³ 40 U/mg), trypsin (from bovine 
pancreas; 12,602 BAEE U/mg), and pronase (from Streptomyces griseus; ³ 45 U/mg) 
were purchased from Sigma-Aldrich and diluted on day of assay. Carboxylesterase (from 
porcine liver; ³ 15 U/mg) was purchased from Sigma-Aldrich and 40U/ml aliquots were 
prepared in buffer and stored at -20°C until use. Pre-cast non-denaturing gradient gels 
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(Mini-PROTEAN TGX Gel 4-20%) and native sample buffer (62.5 mM Tris-HCl, pH 6.8 
containing 40% glycerol and 0.01% bromophenol blue) were purchased from Bio-Rad 
(Hercules, CA).  Butyrylthiocholine iodide (BTChI), p-nitrophenyl acetate (p-NPA), 
ethopropazine, and remaining chemicals and reagents were purchased from Sigma-
Aldrich. 
3.2.2 Copolymer-Complexation of BChE 
Copolymer-BChE complexes (C-BCs) were prepared by Dr. Nicholas Flynn 
(Chemical Engineering, Oklahoma State University). First, three different PLL-g-PEG 
copolymers were prepared using methoxypoly(ethylene glycol, mPEG) containing an 
amine-reactive, n-hydroxysuccinimide ester (NHS) and poly-L-lysine (PLL), of either 
high (30-70 kDa), medium (15-30 kDa), or low (4-15 kDa) molecular weight. A 
sufficient amount of a 50/50 mixture of 2 and 5 kDa mPEG-NHS in PBS (to obtain an 
average 10:1 PEG-PLL grafting ratio) was allowed to react with one of each of the three 
sizes of PLL at room temperature for two hours. A PEG:PLL grafting ratio of 10:1 was 
confirmed by 1H NMR spectroscopy. The resulting copolymers were purified using a 
centrifugal concentrator (10 kDa cutoff), rinsed with ultrapure water, and then 
lyophilized and stored at -20°C until use.  
Electrostatic complexes of the copolymer and rhBChE were prepared essentially 
as reported by Flynn and colleagues (2016) [279]. The copolymer was combined with 
PBS to make a 6 mg/ml solution. An aliquot (7.5 µl) is added drop-wise to 25 ml of 
rhBChE (0.27 mg/ml) at room temperature for one hour with constant mixing. 
Copolymer-to-protein mass ratio was kept at 7:1 in all reactions. After one hour, 5 µl of 
glutaraldehyde (0.025% v/v in PBS) was added drop-wise and the reaction proceeded for 
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another three hours at room temperature to cross-link amino groups and stabilize the 
copolymer-BChE complexes [9]. Free enzyme preparations are made by adding vehicle 
only (PBS) instead of either copolymer or glutaraldehyde, but with all other conditions 
being the same. The resulting free and copolymer-complexed enzyme preparations 
contain the same amount of BChE protein (0.18 mg/ml). All enzyme preparations were 
stored at 4°C until use. 
3.2.3 Colorimetric BChE Assay 
A modified Ellman method was used to measure enzyme activity [280, 281]. All 
enzyme preparations were serially diluted with PBS containing bovine serum albumin 
(BSA; 0.05% w/v) to stabilize enzyme activity [282, 283]. Twenty-five µl (about 11 ng 
protein) of a diluted enzyme preparation was added to wells in a flat bottom 96-well plate 
(Fisher Scientific; Hampton, NH). To initiate the reaction, a cocktail containing BTChI (1 
mM final concentration) and DTNB (5,5’-dithio-bis-(2-nitrobenzoic acid)) (100 µM final 
concentration) in 10 mM Tris-HCl containing 1 mM EDTA, pH 7.2 was added to bring 
the volume of each well to 200 µl. Plates were incubated at 37°C and kinetic 
measurements are completed within five minutes using a Spectramax 340PC microplate 
reader (Molecular Devices; Sunnyvale, CA). Enzyme activity was estimated based on the 
rate of appearance of the reaction product, 2-nitro-5-thiobenzoate (ε = 14,150 M-1 cm-1) at 
412 nm, and was uniformly corrected for non-enzymatic substrate hydrolysis. 
3.2.4 Choline Substrate Kinetics 
Substrate kinetics of free and copolymer-complexed BChE were evaluated using a 
range of concentrations of BTChI (10 µM to 1 mM). Quadruplicate reactions were 
followed photometrically under the conditions described in section 3.2.3. Vmax and KM 
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were determined using non-linear regression using the Michaelis-Menten equation. 
Turnover number, kcat, was calculated using the relationship Vmax = kcat[E], where [E] 
represents the concentration of BChE active sites in the reaction. 
3.2.5 Inhibitor Kinetics 
Inhibitor kinetics with the free and copolymer-complexed enzymes were 
compared using the organophosphorus inhibitors paraoxon (PO), 
diisopropylfluorophosphate (DFP), and echothiophate (EthP) as well as the carbamate 
inhibitor pyridostigmine bromide (PB). All inhibitors were diluted on the day of assay 
with 10 mM Tris-HCl containing 1 mM EDTA, pH 7.2 and ethanol (final concentration, 
0.06% v/v). First, 12.5 µl of enzyme (about 11 ng protein) was placed in wells of U-
bottom 96-well plates (Corning; Corning, NY). At specified times (0-10 minutes), 12.5 µl 
of vehicle or one of a range of concentrations of one of the inhibitors was added in 
duplicate. The reactions were allowed to pre-incubate at 37°C with continuous shaking. 
Residual BChE activity was then measured by adding 175 µl of the cocktail containing 
substrate and color reagent (see section 3.2.3). After range finding studies, four 
concentrations of each inhibitor were selected to evaluate concentration- and time-
dependent inhibition of BChE activity: paraoxon (50, 100, 250 and 500 nM), DFP (5, 10, 
25 and 50 nM),  echothiophate (100, 250, 500 and 750 nM), and pyridostigmine (10, 25, 
50 and 100 µM). Results of the inhibitor kinetics were evaluated as described by 
Richardson and coworkers [284]. Briefly, primary plots were constructed using the 
natural log of residual BChE activity versus time with each of the different enzyme 
preparations with the four concentrations of each of the selected inhibitors. Secondary 
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plots of the negative slope of each primary plot versus the concentration of inhibitor 
yielded straight lines with a slope = ki. 
3.2.6 Sequestration (Bioscavenging In Vitro) 
An indirect enzyme inhibition assay was used to evaluate in vitro bioscavenging 
potential of free enzyme and C-BCs using paraoxon as the inhibitor. Carboxylesterase 
(CarbE) was used as a marker enzyme and assayed essentially as described by Wei and 
colleagues [285]. First, in vitro sensitivity of CarbE to paraoxon was evaluated. CarbE 
(10 µl, 0.4 U/ml) was added to wells in a 96-well plate followed by addition of 10 µl of 
either vehicle (10 mM Tris–HCl containing 1 mM disodium EDTA and 4% ethanol, pH 
7.2; Tris-E/4% EtOH) or paraoxon (0.3–1000 nM). Reactions were pre-incubated for 20 
min at 37°C before adding substrate (p-nitrophenyl acetate, 3 mg/ml in acetonitrile). 
Absorbance change at 405 nm was monitored in kinetic mode at 37°C using a 
Spectramax 340PC microplate reader (Molecular Devices; Sunnyvale, CA). A 
concentration of paraoxon that elicited near complete inhibition of CarbE was chosen for 
further use in the in vitro bioscavenger assay.  
Paraoxon inactivation in vitro (as a measure of bioscavenger potential) was 
evaluated essentially as described above, but with an additional pre-incubation step. In 
1.5 ml Eppendorf tubes, 6 µl of either vehicle (PBS containing 0.05% w/v BSA) or one 
of a series of dilutions of either the free or the copolymer-complexed enzyme is added to 
6 µl of either vehicle (Tris-E/4% EtOH) or paraoxon (40 nM), followed by incubation at 
37°C for 20 minutes in a reciprocating water bath. Twelve µl of CarbE (0.4 U/ml in Tris-
E) was then added to each tube and incubated for another 20 minutes under the same 
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conditions. The tubes were then transferred to ice to stop the reaction and aliquots (20 µl) 
were added to wells in a cold 96-well plate. Tris-E buffer (177 µl) was added to each well 
followed by addition of 3 µl of a mixture of p-nitrophenyl acetate (3 mg/ml) and 
ethopropazine (a specific inhibitor of BChE, 10 µM final) in acetonitrile. Ethopropazine 
was added to block any residual BChE from hydrolyzing the CarbE substrate. 
Absorbance change at 405 nm was recorded in kinetic mode as above. CarbE activity in 
the reactions that are pre-incubated with only vehicles (without BChE or PO) was defined 
as vehicle control. 
3.2.7 Heat Inactivation 
 Heat inactivation was studied essentially as described by Gall and coworkers 
[286]. Fifty-five µl aliquots of free and copolymer-complexed enzymes (0.44 µg/ml in 
PBS containing 0.05% w/v BSA) were incubated at a range of temperatures (in 5° 
intervals from 30-75°C) for one hour, and then transferred to ice to stop the inactivation 
reaction. Aliquots were subsequently measured for residual BChE activity as described in 
section 3.2.3.  The data were plotted as percent of control activity versus log-transformed 
temperatures, with 100% activity defined by BChE activity in respective samples 
incubated at 4°C. Time course studies were conducted similarly by incubating 55 µl 
aliquots of enzyme preparations at a constant temperature (55°C) and removing samples 






3.2.8 Protease Inactivation 
 Time-dependent proteolytic inactivation of the free rhBChE and C-BCs was 
evaluated using trypsin, chymotrypsin, and pronase in PBS. Concentrations of 
chymotrypsin (37.5 µg/ml), trypsin (187.5 µg/ml), and pronase (25 µg/ml) were selected 
based on relatively similar degrees of time-dependent inactivation. The free and 
copolymer-complexed enzymes (0.44 µg/ml in PBS containing 0.05% w/v BSA) was 
incubated with either trypsin, chymotrypsin, or pronase at 37°C. Aliquots (1.5 µl) were 
removed at 0, 1, 2, 4, 6 and 8 hours and diluted (1:1000) into ice cold buffer to stop the 
reaction. Diluted samples were assayed for residual BChE activity using the method 
described above (section 3.2.3).  
3.2.9 Native BChE Activity Gels 
Activity gels were performed using inactivated samples (heat and trypsin 
digested). Samples used for activity gels were prepared similarly to those described in 
described in section 3.2.7 and 3.2.8. In brief, BChE or MMW C-BCs (both 0.44 µg/ml) 
were incubated at 55℃ and 5 µl aliquots were transferred to ice after one minute or eight 
hours of pre-incubation. For trypsin inactivation, enzymes were incubated with 187.5 
µg/ml trypsin (final) and 5 µl aliquots were removed at the one hour and eight-hour time 
points. Control samples were prepared similarly, excepting the inactivation procedures. 
To run the gels, the 5 µl samples were mixed with 5 µl native sample buffer and the total 
mixture was loaded into the wells of a non-denaturing gradient gel (4-20%). The gel 
apparatus (Mini-PROTEAN Tetra Cell and PowerPac Universal Power Supply)(Bio-Rad; 
Hercules, CA) was filled with running buffer (25 mM Tris Base and 200 mM glycine in 
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water) and run at a constant 120V. Gels were run for two hours in a cold room before 
removal from apparatus.  
Gels were stained for BChE activity using the method of Karnovsky and Roots 
[287]. The staining solution was composed of 5 mM sodium citrate, 3.15 mM copper 
sulfate, 0.5 mM potassium ferricyanide (added just before staining), and 2 mM BTChI in 
200 mM maleate buffer (adjusted to pH 6.0 day of assay). Gels were placed in the 
staining solution covered from light and placed on a platform shaker for two hours. After 
removal from staining solution, gels were rinsed with deionized water and then 
photographed using an Amersham Imager 600 (GE Healthcare Bio-Sciences; Pittsburg, 
PA). 
3.2.10 Statistical Methods 
All data were derived using at least three independent enzyme preparations. Data 
for substrate and inhibitor kinetic parameters, and sequestration EC50 were analyzed by a 
one-way analysis of variance test (ANOVA) with enzyme type (i.e., free enzyme and 
three PLL-g-PEG-complexed enzymes) as the main factor. When concentration-
dependent inactivation of an enzyme preparation was evaluated (i.e. IC50, EC50) the 
inhibitor concentrations (x-values) were log-transformed and the data fit to a nonlinear 
regression equation (using a variable slope model). The same method was used to 
calculate the T50 value of data resulting from one-hour heat inactivation studies. In time-
dependent heat inactivation studies, the data were fit to a one-phase decay model and the 
resulting half-life values were compared using a one-way ANOVA with enzyme type as 
the main factor. In the protease-mediated inactivation studies, data were also fit to a one-
phase decay model and the resulting curves were compared using an extra sum-of-
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squares F test. Similar to above, the calculated half-life values were compared using one-
way ANOVA. In both cases, the plateau value of the one-phase decay fit was constrained 
between 0-100 because data was reported as percent of residual activity. When post hoc 
tests were warranted, Tukey’s multiple comparisons test was used (unless otherwise 
noted). Statistical significance was defined as a p-value < 0.05 in all cases, and p-values 
resulting from multiple comparisons analysis reported in-text are multiplicity adjusted. 
All statistical tests were conducted using GraphPad Prism software (La Jolla, CA), 
version 6.0. 
3.3 RESULTS 
3.3.1 Catalytic Activity of free rhBChE and C-BCs 
Prior to experimental studies with C-BCs, the activity of recombinant human BChE 
was evaluated following a large dilution (1:200). We found that rhBChE lost significant 
activity following dilution with PBS, and this could be prevented by including BSA in 
the dilution buffer (Fig. 3-1). It has been previously reported that BSA may serve as a 
stabilizer for proteins during dilution [288]. These findings were used as the basis for 
inclusion of BSA in buffers used for subsequent studies with rhBChE and C-BCs.  
In order to determine the effects of copolymer encapsulation on enzyme activity, we 
first compared the activity of free rhBChE and C-BCs. Figure 3-2 shows that activity of 
low, medium, and high molecular weight C-BCs was significantly decreased compared to 
free rhBChE. Because these results suggested that enzyme activity was indeed affected 
by the presence of the copolymer, we evaluated enzyme activity more completely using 
substrate kinetics (Fig. 3-3). Table 3-1 shows the substrate kinetics parameters 
determined using nonlinear regression fit to the Michaelis-Menton equation. The turnover 
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rate (kcat) of all C-BCs was significantly decreased in comparison to the free enzyme (F(3, 
130) = 19.05, p < 0.0001 in all cases), however, further pairwise comparisons revealed no 
differences between the different PLL backbone lengths. The KM of each was not 
significantly decreased, there was, however, a trend toward increasing KMs as the length 
of copolymer backbone increased (LMW<MMW<HMW). The combination of these 

















Figure 3-1. Activity of rhBChE after dilution with PBS or PBS + BSA. Free rhBChE 
(0.18 mg/ml) was diluted 1:200 using PBS or PBS containing 0.5 mg/ml BSA and then 










Figure 3-2. Activity of free rhBChE and C-BCs. Enzyme activity was determined as 
described in section 3.2.3, using 1 mM BTChI as the substrate. Data are reported as 
percent activity in relation to free rhBChE (mean ± SD; n=4). Asterisks indicate a 
significant difference from free rhBChE as determined by one-way ANOVA followed by 










Figure 3-3. Concentration-dependent hydrolysis of BTChI by free rhBChE and C-BCs. 
Each enzyme preparation was incubated with BTChI (10-1000 µM) for 5 min at 37°C 
and activity was measured using a modified Ellman method. Data represent mean ± SD 










Table 3-1. Substrate kinetic parameters (kcat, KM, and kcat/KM) for free rhBChE and C-
BCs. Each enzyme preparation was incubated with butyrylthiocholine (10-1000 µM) for 
5 min at 37°C and activity measured using the photometric method. Data represent mean 
values with 95% confidence intervals in parentheses (n=4). 
 





































3.3.2 Sensitivity of free rhBChE and C-BCs to Inhibition 
While enzyme activity assays provide a means for determining the effect of the 
copolymer-complexation on catalytic function, the primary goal of this formulation is 
inhibitor binding (i.e. bioscavenging activity). Therefore, we evaluated the effect of 
copolymer-complexation on the enzyme’s inhibitor binding capacity using the method 
developed by Aldridge and Reiner in 1972 and refined by Richardson and coworkers 
[283, 287]. Primary plots of inhibition show the natural log of residual enzyme activity 
versus pre-incubation time with varying concentrations of paraoxon, DFP, echothiophate, 
and pyridostigmine. Inhibitor concentrations were chosen to elicit similar free enzyme 
inhibition (as opposed to uniform inhibitor concentrations) due to the large difference in 
inhibitor potency. Figure 3-4 shows the primary plot results of free rhBChE with the four 
inhibitors. Primary plots for each of the remaining conditions yielded linear relationships 
(R2 = 0.93 - 0.99) that extrapolated to zero (Figs. 3-5, 3-6, and 3-7). Negative slopes of 
the primary plots (-k’) were then plotted against inhibitor concentrations to yield 
secondary plots (Fig. 3-8). The secondary plots all had linear relationships (R2 = 0.82 - 
0.98) with slopes equaling ki (summarized in Table 3-2).  
In the case of each inhibitor, there was a statistically significant difference detected in 
the slopes of the secondary plots (paraoxon: F(3,240) = 3.9, p = 0.009; DFP: F(3,288) = 24.87, 
p < 00001; PB: F(3,277) = 24.78, p < 0.0001; EthP: F(3,270) = 194.4, p <0.0001). Post hoc 
analysis with paraoxon revealed a difference between free rhBChE and the HMW 
copolymer preparation only (p = 0.004). In contrast, post hoc analyses with the three 
remaining inhibitors revealed a statistically significant difference between free rhBChE 
and each of the copolymer preparations (LMW, MMW, and HMW) (p < 0.0001 in all 
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cases). Further pairwise comparisons revealed additional significant differences between 
the low molecular weight copolymer versus the high molecular weight copolymer (p < 
0.0001) and the medium molecular weight copolymer versus the high molecular weight 
copolymer (p < 0.0001) only when echothiophate was used as the inhibitor. While 
significant differences were noted with each inhibitor, the extent of the reduction was 
notably different. For example, the inhibitory potency of paraoxon against the BChE 
complexed using the HMW PLL-based copolymer was reduced by 12%, while the 
potency of DFP was reduced by 16-23%, PB by 31-41%, and EthP by 41-60%. Thus, 
kinetic studies suggested that inhibitory potency was reduced with the inhibition of 
copolymer-complexed enzymes in an inhibitor-dependent manner, i.e., minimal changes 
were noted with paraoxon as the inhibitor while differing degrees of reduction in 
inhibitory potency were shown with the other three inhibitors. Note that overall inhibitory 
potency of the four inhibitors against the four enzyme preparations was DFP > paraoxon 













Figure 3-4. Concentration- and time-dependent inhibition of free rhBChE by PO (A), 
DFP (B), PB (C), and EthP (D). Primary plots show the natural log of residual free 
enzyme activity (Vt/V0) versus time of pre-incubation with selected inhibitor 









Figure 3-5. Concentration- and time-dependent inhibition of LMW C-BCs by PO (A), 
DFP (B), PB (C), and EthP (D). Primary plots show the natural log of residual free 
enzyme activity (Vt/V0) versus time of pre-incubation with selected inhibitor 









Figure 3-6. Concentration- and time-dependent inhibition of MMW C-BCs by PO (A), 
DFP (B), PB (C), and EthP (D). Primary plots show the natural log of residual free 
enzyme activity (Vt/V0) versus time of pre-incubation with selected inhibitor 









Figure 3-7. Concentration- and time-dependent inhibition of HMW C-BCs by PO (A), 
DFP (B), PB (C), and EthP (D). Primary plots show the natural log of residual free 
enzyme activity (Vt/V0) versus time of pre-incubation with selected inhibitor 









Figure 3-8. Secondary plots for bimolecular rate constant (ki) determination. Plots 
represent -k’ values (determined from primary plots in Figs. 3-4 to 3-7) versus inhibitor 
concentrations. The slope of these secondary plots determines ki. Data are reported as 









Table 3-2. Bimolecular rate constants (ki) of free rhBChE and C-BCs. Enzymes were 
exposed to either paraoxon (PO), diisopropylfluorophosphate (DFP), pyridostigmine 
bromide (PB) or echothiophate (EthP) at different inhibitor concentrations for different 
times, and then residual enzyme activity was measured as in section 3.2.3. Data represent 
mean values with 95% confidence intervals in parentheses (n=3). 
 
* Indicates a significant difference compared to free rhBChE.  
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3.3.3 In Vitro Scavenging Capacity of C-BCs Against Paraoxon 
To further evaluate the effect of copolymer-complexation on bioscavenging capacity, 
we conducted an in vitro scavenging assay using a marker enzyme, carboxylesterase 
(CarbE), and paraoxon as a model OP compound. During a pre-incubation step, free 
rhBChE and C-BCs were separately incubated with PO, followed by addition of CarbE. 
If unbound paraoxon was remaining following the pre-incubation step, it would inhibit 
the added CarbE. Prior to this assay, the sensitivity of CarbE to PO was determined (Fig. 
3-9), and a PO concentration was selected that elicited near 100% CarbE inhibition (20 
nM). The BChE-specific inhibitor ethopropazine was included during the final CarbE 
activity quantitation to prevent excess (i.e. unbound) BChE from hydrolyzing the CarbE 
substrate. A preliminary assay was also conducted with ethopropazine to select a 
concentration which inhibited BChE but not CarbE (Fig. 3-10).  
Figure 3-11 shows there was essentially complete CarbE inhibition when paraoxon 
was pre-incubated with only PBS before adding the marker enzyme. In contrast, pre-
incubation of paraoxon with free rhBChE (Fig. 11A; F(7,32)= 90.27, p < 0.0001) or C-BCs 
made with low molecular weight PLL- (Fig. 11B; (7,14) = 8.75, p = 0.0003), medium 
molecular weight PLL-(Fig. 11C; F(7,16) = 55.82, p < 0.0001) and high molecular weight 
PLL- (Fig. 11D; F(7,24) = 49.20, p < 0.0001) based copolymers protected against CarbE 
inhibition in a relatively similar, concentration-dependent manner. Percent of residual 
CarbE activity is proportional to the amount of PO sequestered (i.e. if 100% CarbE 
activity remains, then 100% of PO molecules were sequestered in the first pre-incubation 
step). Therefore, a plot of percent sequestration versus log of the protein concentration 
allowed for estimation of relative in vitro scavenging capacity (Fig. 3-12). The EC50 (i.e. 
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amount of rhBChE necessary to protect 50% of CarbE activity) for the free enzyme was 
48.8 nM (95% confidence interval [CI] = 45.6 - 52.3). The EC50 for the C-BCs were 53.6 
nM (CI = 43.2 - 66.4), 46.3 nM (CI = 42.5 - 50.4), and 59.3 nM (CI = 54.0 - 65.2) for 
LMW, MMW, and HMW C-BCs, respectively. Post hoc analyses determined that the 
HMW PLL copolymer was significantly different than both free rhBChE (p = 0.02) and 

















Figure 3-9. CarbE sensitivity to inhibition by paraoxon. CarbE (4 mU) was pre-incubated 
with paraoxon (0.3 - 1000 nM) for 20 minutes at 37°C, prior to addition of the substrate 
(p-nitrophenyl acetate, 50 µM) and measuring residual activity. Data are mean values ± 











Figure 3-10. Sensitivity of CarbE and BChE to ethopropazine. CarbE (4 mU) or BChE 
(73.7 ng) was assayed using p-nitrophenyl acetate (50 µM final) containing 
ethopropazine (1-100 µM, final). Data are presented as percent of activity when no 
ethopropazine was added (mean values; n=1). Based on these data, a 10 µM final 









Figure 3-11. In vitro inactivation of paraoxon by free rhBChE and C-BCs. Dilutions (1:8 
to 1:40) of free enzyme (A) and C-BCs using either the (B) low MW-, (C) medium MW- 
or (D) high MW PLL-based copolymer were first pre-incubated with either vehicle or PO 
(20 nM) for 20 min at 37°C. A marker enzyme, CarbE, was then added and the mixture 
incubated for another 20 min at 37°C. Remaining CarbE activity was measured by 
addition of substrate (p-nitrophenyl acetate) with ethopropazine (BChE-specific 
inhibitor). Activity in reactions pre-incubated without paraoxon and BChE were used as 
vehicle controls (VEH). Data are plotted as percent of control (mean ± SD) from 3 to 4 
independent preparations. Asterisks indicate significant differences as compared to the 





Figure 3-12. In vitro sequestration capacity of free rhBChE and C-BCs. Several 
concentrations of free rhBChE and low-, medium- and high molecular weight PLL C-
BCs were first pre-incubated with either vehicle or paraoxon (20 nM) for 20 min at 37°C. 
CarbE was then added and the mixture incubated for another 20 min at 37°C. Remaining 
CarbE activity was measured by addition of substrate (p-nitrophenyl acetate) with 
ethopropazine (BChE-specific inhibitor). Data were plotted as percent sequestration (i.e. 
percent CarbE activity compared to inhibitor-free controls) (mean ± SD) from 3 to 4 






3.3.4 Sensitivity to Inactivation by Proteases and Heat 
While the previous assays characterized the effect of copolymer-complexation on 
enzyme inhibition and catalytic activity, we also characterized the effect of copolymer-
complexation on enzyme stability. Changes in in vitro heat sensitivity may affect shelf 
stability and storage conditions. Figure 3-13 shows comparative effects of a one-hour 
exposure to increasing temperatures on enzyme activity in the free rhBChE and C-BCs. 
The mean temperature at which 50% of the esterase activity was inactivated (T50) with 
the free enzyme was 45.6℃ (CI = 45.0 - 46.3). The T50 for the low, medium, and high 
molecular weight C-BCs were 57.7℃ (CI = 56.9 - 58.6), 56.5℃ (CI = 56.2 - 58.6), and 
51.2℃ (CI = 50.2 - 52.3), respectively. The difference in the T50 between the free 
enzyme and C-BCs was statistically significant in all cases (p < 0.0001). Further pairwise 
comparisons showed that LMW and MMW C-BCs were significantly different from the 
HMW C-BCs (p < 0.0001) . Next, a temperature near the T50 (55℃) was selected to 
perform an extended time course of inactivation of enzymatic activity in all preparations 
(Fig. 3-14). In agreement with the above results, nearly all free enzyme activity is lost 
after one hour at 55℃. The C-BCs retained partial activity (17 - 42%) up to 15 hours. 
The inactivation of all enzyme preparations fit well with a one-phase decay model (R2 = 
0.94 - 0.97), and the calculated half-lives were significantly different (F(3, 192) = 69.41; p < 
0.0001). Post hoc tests determined that the half-lives for the low- (70.0 min; CI = 56.8 - 
91.2), medium- (51.5 min; CI = 42.2 - 66.0), and high- (24.8 min; CI = 21.2 - 29.9) 
molecular weight PLL C-BCs were all significantly different from the free enzyme (1.2 
min; CI = 1.0 - 1.6) (p < 0.0001 in all cases). Pairwise comparisons between different 
copolymer weights did not reveal any further differences.  
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 We also performed an assay with proteolytic enzymes, aiming to gain information 
on in vivo enzyme stability. Figure 3-15 compares the inactivation of BChE activity in 
the free and C-BCs following exposure to chymotrypsin, trypsin, and pronase. Pronase is 
a protease mixture from Streptomyces griseus which digests proteins into single amino 
acids [289]. Modeling these inactivation data with a one-phase decay model led to 
relatively high R2 values for free rhBChE and C-BCs (R2 = 0.75– 0.99). With each 
protease, an extra sum-of-squares F test determined that the best-fit curves for the free 
enzyme and C-BCs were statistically different from each other (chymotrypsin: F(9,72) = 
16.52; trypsin: F(9,60) = 45.01; pronase: F(9,60) = 10.02, all p < 0.0001). Approximately 
28% of free rhBChE activity was lost after one hour of incubation with chymotrypsin, 
with over 90% inactivation by eight hours. This same concentration of chymotrypsin 
reduced BChE activity by 17-22% in the C-BCs at one hour, and by eight hours between 
53-75% loss of activity was noted. When trypsin was used, free enzyme activity was 
reduced by 44% at one hour while C-BCs lost between 21-22% activity. The separation 
between free enzyme and C-BC inactivation becomes greater after eight hours of 
incubation; free enzyme was 85% inactivated, and the inactivation of C-BCs was 
between 35-57%. When pronase was used, the free enzyme again appeared more 
sensitive than the copolymer-complexed enzymes (e.g., at 8 h, >95% inactivation was 
noted with free enzyme but 69-84% with the three copolymer-complexed enzymes). 
Interestingly, there were no significant differences detected in the inactivation half-life 
between the free enzyme and C-BCs with any of the tested proteases. Overall, these data 
suggest that a proportion of the BChE molecules in the C-BCs may be effectively 
shielded from the selected proteases and therefore could be more stable in vivo.  
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 Enzyme activity following physical (i.e. heat) or biological (i.e. protease) 
inactivation was also visualized using native activity gels (Fig. 3-16). Free rhBChE 
control samples (lanes 2A and 2B) were composed primarily of monomers, with dimers 
and tetramers also present. Following one minute of heat treatment, monomeric activity 
was decreased, while activity in the tetramers and dimers appeared to remain relatively 
consistent. After eight hours of heat treatment, there was no remaining activity visible in 
the gel. This observation is supported by the colorimetric assay data. Trypsin inactivation 
of free rhBChE (one-hour incubation) resulted in active enzyme fragments with a 
molecular weight between that of the dimers and tetramers. While the dimeric activity 
band was greatly decreased, the overall amount of activity resulting from BChE 
monomers was minimally decreased. It is likely that disassociated tetramers and dimers 
contribute to the seemingly resistant monomeric activity. Following eight hours of trypsin 
inactivation, most of the free enzyme activity was inactivated, with the remaining activity 
arising primarily from BChE monomers. The majority of the MMW C-BCs did not 
migrate into the gel, possibly due to the large size of copolymer particles. The visible 
smearing underneath the main bands could be a result of smaller sized copolymers, as 
previous studies have suggested that the diameter of the C-BCs range from ~15-65 nm 
(median = 35 nm) [290]. After eight hours of inactivation, visible staining of MMW C-








Figure 3-13. Heat inactivation of free rhBChE and C-BCs. Samples of the different 
enzyme preparations were incubated at 30-75℃ for one hour, and then transferred to ice 
before being assayed for residual BChE activity using the colorimetric method described 











Figure 3-14. Time course of heat inactivation of free rhBChE and C-BCs. The different 
enzyme preparations were pre-incubated at 55℃, with samples being removed at 
intervals up to 900 minutes and assayed for residual BChE activity using the colorimetric 
method described in section 3.2.3. Data are reported as percent of activity at time 0 (mean 










Figure 3-15. Protease-mediated inactivation of free rhBChE and C-BCs. The different 
enzyme preparations (low-, medium-, and high- molecular weight PLL) were incubated 
with either chymotrypsin, trypsin or pronase at 37℃ and residual BChE activity was 
measured colorimetrically for up to eight hours. Data are reported as percent of activity at 
time 0 and fit with a one-phase decay model (mean ± SD; n = 3–4 independent replicates 




Figure 3-16. Native activity gels of free rhBChE and MMW C-BCs following physical 
and biochemical inactivation. Enzymes were either pre-incubated at a high temperature 
(55℃) (Panel A) or with trypsin (187.5 µg/ml at 37℃)(Panel B), and 5 µl samples were 
withdrawn at one minute (heat-inactivation), one hour (trypsin inactivation), and eight 
hours (both). Samples were run on non-denaturing gradient gels, followed by staining for 
BChE activity using the method of Karnovsky and Roots [287]. A sample of purified 
tetrameric human serum BChE (lane 1, both panels) was used as a marker enzyme. In 
both panels, lane 2 contains control (no inactivation) free rhBChE samples, and lanes 3 
and 4 contain inactivated free enzyme samples (either 1 min and 8 h [A] or 1 h and 8 h 





Poly(ethylene glycol) modification of proteins has been used to improve 
pharmacokinetic and pharmacodynamic properties of protein therapeutics [291]. BChE is 
an effective prophylactic against OP intoxication, though its circulatory half-life, among 
other things, make widespread implementation difficult. Therefore, the effect of 
PEGylation on BChE pharmacokinetics has become an area of interest [272, 292]. 
Gaydess and colleagues developed a PEG grafted poly-l-lysine copolymer which 
electrostatically assembled into a complex with BChE, and found that these complexes 
slightly increased the delivery of BChE across the blood brain barrier [9]. Previous 
studies in our lab further characterized the effects of copolymer:protein and PEG grafting 
ratios on these complexes [10]. This study aimed to further understand the influence of 
these polymeric constituents (made with either a low, medium, or high molecular weight 
PLL) on enzyme characteristics including substrate and inhibitor kinetics, in vitro 
scavenging capacity, and sensitivity to inactivation by heat and proteases.   
 As initial assays noted a marked reduction in catalysis in C-BCs using a single 
substrate concentration, we compared the kinetics of butyrylthiocholine hydrolysis 
between free and copolymer-complexed enzymes. The results generally agreed with our 
initial findings using a single substrate concentration. The turnover rate, kcat, was 
significantly reduced with all three copolymer-complexed enzymes (Table 3-1). 
PEGylation has been found to decrease catalytic activity in other enzymes as well [12, 
293, 294], though in some cases PEGylation has little or no effect on enzyme activity [13, 
272]. It is also common for PEGylation to decrease binding affinity [12], though under 
our conditions KM was not significantly increased. As there did appear to be a trend 
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towards increasing KM values in our study, however, it is possible that further replicates 
could detect significant findings with the C-BCs as well. These data suggested that some 
BChE molecules within the C-BCs may interact with substrate in a relatively similar 
manner as the free enzyme, while others have lesser access to the substrate, leading to a 
reduction in substrate hydrolysis and catalytic efficiency. We postulated that charge 
repulsion may result from interaction of the quaternary nitrogen on the substrate with any 
free cationic residues of PLL, leading to hindered access of substrate to the BChE active 
site.  
 BChE exhibits complex substrate kinetics, based on location of the active site 
deep within a “gorge” in the enzyme quaternary structure, the possibility of additional 
substrate molecules binding to residues at the entrance to the gorge, and related 
conformational changes between two forms of the enzyme with differing catalytic 
activities [295, 296]. The end result is that classical Michaelis-Menten kinetics are 
typically not observed with charged substrates of BChE across a wide range of substrate 
concentrations. We selected substrate concentrations (10-1000 mM) to minimize the 
possibility of substrate inhibition, and our data fit relatively well with the Michaelis-
Menten model. While our substrate kinetics evaluations do not fully describe the 
complexity of BChE-substrate interactions in the catalysis of butyrylthiocholine, they do 
support our original observation that the copolymer-complexed enzymes have an overall 
reduction in catalytic efficiency compared to the free enzyme.  
 We then characterized the kinetic interactions between BChE (as free or 
copolymer-complexed enzyme) and four different anticholinesterases. As we 
hypothesized that charge repulsion could potentially play a role in the apparent loss of 
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enzyme activity in the copolymer-BChE complexes, we evaluated kinetics of inhibition 
using both neutral (paraoxon and DFP) and positively charged (pyridostigmine and 
echothiophate) inhibitors. While the inhibitory potency of paraoxon was slightly 
decreased in the HMW C-BCs only (12% reduction), ki values with DFP were 
significantly reduced (16-23%) with all three copolymer-complexed enzymes, suggesting 
that charge repulsion could not completely explain differential changes in catalysis and 
inhibition between charged and neutral ligands. With the positively charged inhibitors, 
however, inhibitory potency (ki) was indeed reduced to a greater extent (pyridostigmine, 
32-41% and echothiophate, 41-60% reduction; Table 3-2). Together, these findings 
suggest that a positive charge on an inhibitor (or substrate) could impair its access to the 
copolymer-complexed enzyme because of the polycationic nature of the PLL backbone, 
but that other factors, e.g., lipophilicity, might also influence ligand binding to 
copolymer-complexed enzymes. The extent of reduction in ki with the four inhibitors 
studied generally agrees with observed or predicted logKow values (paraoxon, 1.98; 
DFP, 1.17; pyridostigmine, 0.94; echothiophate, -2.25) [297]. Further studies using a 
larger set of substrates and inhibitors with a wider range of physicochemical properties as 
well as copolymers with differing properties (e.g., varying sizes, residual cation density) 
could provide more insight into the molecular basis for selective interactions between 
ligands and copolymer-complexed enzymes.  
 Regardless of the molecular basis for differential binding of inhibitors to 
copolymer-complexed enzymes, reduced inhibitory potency with the copolymer-
complexed enzymes could have practical implications in their use as bioscavengers. It is 
estimated that ideal bioscavengers should be able to completely detoxify an OP exposure 
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within one circulation time [298]. Thus, significant changes in the rate of inhibitor 
binding are an important parameter to consider in addition to the upper limit of inhibitor 
binding. For example, the apparent similar interactions between paraoxon and all enzyme 
preparations (reflected as similar ki values) suggest that the copolymer-complexed 
enzymes would be equally effective as bioscavengers compared to the free enzyme. The 
results from the in vitro scavenging assay with paraoxon (Fig. 3-12) generally agreed 
with those from the inhibition kinetics assays (i.e. LMW and MMW C-BCs had the same 
ability to sequester paraoxon while the HMW C-BCs were slightly but significantly 
decreased). These results suggest that inhibitor kinetics are a better measure of 
bioscavenging potential than catalytic activity, though further in vitro scavenging assays 
(using different inhibitors) would be necessary to confirm this. Moreover, the lower ki for 
pyridostigmine with a complexed enzyme suggests this inhibitor may have more 
difficulty binding to the active site region and therefore could be scavenged less 
effectively than by the free enzyme. Since pyridostigmine can be used as a prophylactic 
agent against OP toxicants by inhibiting acetylcholinesterase in the peripheral nervous 
system, lesser interaction with a copolymer-complexed enzyme could be an advantage if 
both pyridostigmine and an OP toxicant were present. These considerations are tempered 
however by the relatively small degree of change in inhibitory potency noted with all of 
the copolymer-complexed enzymes.  
 Each of the C-BC preparations tested was also more thermostable than free 
rhBChE (Figs. 3-13 and 3-14). Thermal stability of enzymes has been used for over a 
century to characterize protein function [299]. Enzymes undergo an irreversible 
conformational change at higher temperatures, leading to a dramatic loss of activity 
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above a certain temperature. Prepared enzyme prophylactics may be exposed to high 
temperatures during storage or use in battlefield scenarios, which may lead to enzyme 
aggregation and activity loss. While PEGylation has been found to increase temperature 
resistance in some systems [12, 13], PEGylation of the catalytic bioscavenger OPH 
slightly decreased the thermal stability of the enzyme [277]. The noted increase in 
thermostability of our copolymer-complexed BChE could be indicative of a higher in 
vivo and “shelf” stable preparation, which could be an advantage of copolymer-
complexed enzymes in further bioscavenger development and application.  
 The current study has also demonstrated that our C-BCs were more resistant to 
the proteases chymotrypsin, trypsin, and pronase (Fig. 3-15). With each protease, the 
free, uncomplexed enzyme lost activity to a greater extent over the eight-hour incubation 
period compared to copolymer-complexed enzymes. These results support previous 
findings that PEGylated BChE, among other enzymes, are generally more resistant to 
protease degradation [13, 272, 300]. The higher plateau of inactivation noted with the 
copolymer-BChE complexes could be an indicator that some BChE molecules within the 
polyionic complexes are shielded from interaction with proteases. This was further 
supported by the native activity gels (Fig. 3-16, panel B). At each time point, the overall 
staining density decreased slightly but the distribution did not, suggesting that enzyme 
activity which remains inside the copolymer is somewhat shielded from inactivation. 
Regardless, these findings suggest that the copolymer-complexed enzymes could be more 
resistant than the free enzyme in vivo to degradation by endogenous proteases.  
 In general, the copolymer-complexed enzymes appeared to have different 
sensitivity to inactivation by inhibitors, proteases and heat. There were however, some 
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instances where the type of complex (i.e., based on the size of the PLL used in the 
copolymer) influenced sensitivity. When inhibition kinetics were compared using 
echothiophate as the inhibitor, ki was significantly different with all three copolymer-
complexed enzymes compared to the free enzyme, but complexes made with copolymer 
having the high molecular weight PLL was reduced further than in the other two types of 
complexed enzyme. In vitro scavenging assays demonstrated that the HMW copolymer 
was significantly different from free rhBChE and the MMW C-BCs, but no other 
differences were detected. Moreover, heat inactivation of the complexed enzymes 
appeared copolymer-dependent, i.e., the free enzyme was inactivated at lower 
temperatures than complexes with the high molecular weight PLL, but complexes made 
with the low and medium molecular weight PLL were even more resistant. Thermal 
stability resulting from PEGylation has been previously shown to be dependent on PEG 
molecular weight [12], though interestingly our findings seemed to suggest a negative 
correlation (i.e. the high molecular weight CBCs were the least stable). Other studies 
have also suggested factors such as PEG type (branched versus linear), PEG molecular 
weight, and grafting ratio affect the pharmacokinetics and pharmacodynamics of 
PEGylated enzymes [274, 301, 302]. Our results support the notion that PEG molecular 
weight differentially affects the properties of PEGylated enzymes. Furthermore, these 
findings suggest that tuning of copolymer properties could lead to further optimization 
for ligand binding and bioscavenger efficacy/selectivity as well as stability.  
 In conclusion, complexes of recombinant human BChE with PLL- g-PEG 
copolymers lose partial catalytic activity but differentially retain the ability to interact 
with inhibitors in a structure-dependent manner. While increased resistance to heat and 
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protease inactivation was noted, any potential benefits of increased stability could be 
countered, however, if the enzyme’s ability to interact with toxicants was reduced. 
Kinetic analyses suggest that the copolymer, via electrostatic, hydrophobic or possibly 
other interactions, may influence how a chemical ligand interacts with the enzyme active 
site. Understanding how proteins and polymers interact within these complexes may aid 








EVALUATION OF  SURFACE PEPTIDE NETWORKS ASSOCIATED WITH 
CATALYSIS IN A VARIANT (BCHEG117H) FOR RE-ENGINEERING 
 
4.1 INTRODUCTION 
While the safety and efficacy of BChE is well-demonstrated in animal models, 
translation to widespread clinical use is difficult. Pharmacokinetic improvements using 
PEG and cell carriers may provide an improved dosing schedule; however, the 
stoichiometric nature of BChE results in an inherent pharmacodynamic drawback. 
Although a 200 mg dose of BChE is considered effective, a high OP exposure may 
overcome BChE’s scavenging ability. In contrast to the stoichiometric nature of the 
native enzyme, the G117H mutant of BChE has catalytic activity against some OPs; 
however, its low hydrolytic rate makes further development necessary to function as a 
biologically relevant catalytic scavenger.  
An emerging concept in enzyme function is that dynamic motions of peptide 
sequences on an enzyme’s surface, distant from the active site region, can influence the 
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rate of a catalytic reaction. It has been proposed that catalytic rate is affected by 
thermodynamical coupling of the hydration-shell, the bulk solvent, and the catalyzed 
reaction [303]. For a number of enzyme systems, networks of conserved residues have 
been discovered that span from the surface of the protein to the active-site region, 
effectively coupling with the catalytic reaction mechanism [304]. In fact, enhancing 
energy flow through these networks may be a general approach for increasing enzyme-
mediated catalysis. Conformational fluctuations in such peptide networks were shown to 
coincide with catalysis in the serine hydrolase lipase B from Candida antarctica, which 
utilizes the same catalytic triad as BChE and other serine hydrolases [15]. Importantly, 
insertion of a photosensitive azobenzene bridge joining the flexible surface loops on C. 
antarctica lipase B allowed enhanced photostimulation of catalysis. It is proposed that 
energy transfer from the surface loop to the catalytic site is influenced by the position, 
number, and the physicochemical nature of the peptides within the sequence. Thus, 
increasing the length of this loop and facilitating its interaction with the solvent may 
increase catalytic activity via increased energy transfer. 
The major goal of Aim 2 was to characterize the catalytic activity of mutants of 
BChEG117H with systematically modified surface loops. We hypothesized that applying 
these principles to BChEG117H would aid in the development of a rationally-designed 
mutant with increased catalytic activity towards OP compounds. Based on BLAST 
analyses, a similar enzyme (serine carboxypeptidase) was found with a surface network 
having similar residues as noted in BChE, but with a higher number of peptides. 
Molecular dynamics simulations suggested that increasing the number of peptides in the 
loop may increase fluctuation of the loop and consequently increase energy transfer to the 
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active site. Using these data, a set of six loop mutants was expressed containing three 
additional residues. We estimated the kinetic parameters for substrate hydrolysis using a 
choline ester (butyrylthiocholine) and OP (paraoxon) substrate. To further characterize 
the ability of these mutants to reactivate following OP binding, resistance to inhibition 
and enzyme reactivation (k3) assays were conducted using the OP inhibitors paraoxon, 
DFP and echothiophate.  The set of six loop-mutant enzymes and four substrates 
(butyrylcholine, paraoxon, DFP, echothiophate) were also evaluated computationally to 
determine the dynamics of each mutant.  
4.2 MATERIALS AND METHODS 
4.2.1 Chemicals 
Paraoxon (O,O’-diethyl-p-nitrophenyl phosphate; PO) (98.6% purity by HPLC) 
was purchased from ChemService (West Chester, PA). A 10 mM stock solution of 
paraoxon was prepared in 100% dry ethanol and kept desiccated under nitrogen at -80°C 
until use. Diisopropylfluorophosphate (2-[fluoro(propan-2-
yloxy)phosphoryl]oxypropane; DFP) (99% purity by NMR) was kindly provided by Dr. 
Derik Heiss at Battelle Memorial Institute (Columbus, OH) and stored as provided at _-
80°C [278]. Echothiophate iodide (2-
diethoxyphosphorylsulfanylethyl(trimethyl)azanium; EthP) was originally obtained from 
Wyeth-Ayerst and was a kind gift from Dr. Oksana Lockridge (University of Nebraska, 
Omaha, NE). Butyrylthiocholine iodide (BTChI), 5,5'-dithio-bis-(2-nitrobenzoic 





4.2.2 Molecular Simulations of BChEG117H 
Molecular dynamics (MD) simulations were performed in collaboration with Dr. 
Pratul Agarwal (Oklahoma State University). MD simulations were performed to 
evaluate BChEG117H and BChEG117H-derived loop mutants interacting with four substrates 
(butyrylcholine, paraoxon, echothiophate, and DFP) using AMBER v14 [305]. In all 
cases, simulations were performed using NVIDIA GPUs and AMBER’s pmemd.cuda 
simulation engine using the ff14SB force field, as described previously[306-308]. 
Coordinates for BChE (4BDS) and acetylcholine (4BDS) are available in the protein data 
bank [309, 310], and served as templates to build the desired enzyme/substrate complex 
in AMBER’s LEaP program. During the preparation step, each complex was neutralized 
using counter-ions and solvated using explicit SPC/E water molecules with a 10 Å 
minimum distance between the protein and the edge of the periodic box. After 
preparation, the system was equilibrated as described previously [311]. Production 
simulations were run under constant energy conditions (NVE ensemble) with an initial 
temperature of 300 K. These simulations ran for 200 nanoseconds (ns) with a time-step of 
2 femtoseconds (with SHAKE applied to bonds and angles involving hydrogens). 
Computational snapshots were stored every 20 picoseconds, resulting in 10,000 
coordinates for further analysis.  
 Protein flexibility was calculated using the aggregated root-mean-square-
fluctuations for top 10 quasi-harmonic modes (RMSF10). This analysis was done using 
AMBER’s ptraj analysis program. The RMSF10 method captures the slow intrinsic 
“breathing” which occurs during enzyme catalysis, as opposed to random fast motions 
[312]. Prior to this analysis, the trajectory coordinates were aligned to remove any 
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influence of molecular rotation on the results. The energy from the enzyme-substrate 
interactions were calculated based on a previously developed protocol [311, 313]. All 
enzyme-substrate atom pairs were evaluated to calculate the total electrostatic and van 
der Waals energy between them. The results reflect the average energy sum of the 10,000 
snapshots collected over 200 ns. 
4.2.3 Expression of Selected Recombinant Loop Mutants 
Production of loop-mutant BChE was conducted by Krishna Bhattarai and Dr. 
Haobo Jiang (Entomology & Plant Pathology, Oklahoma State University). We 
constructed a monomeric BChEG117H mutant (control with no insertions) and six 
monomeric BChEG117H loop mutants with three amino acid insertions into the protein 
sequence (between residues 278-285) with an identity of ENX, keeping the glutamate and 
asparagine insertions constant but varying “X” with one of six different amino acids (A, 
G, I, P, R, and T). The constructs of all seven were cloned into the pMFH6 vector to 
express the mutants with a hexahistidine tag at the C-terminus. In vivo transposition of 
the expression cassette into a bacmid in DH10Bac cells, isolation of recombinant bacmid 
DNA, and transfection of the recombinant bacmid DNA into Spodoptera frugiperda Sf9 
cells to generate recombinant baculovirus were performed according to the Bac-to-Bac 
Baculovirus Expression System (Invitrogen Life Technologies), The baculovirus stock 
was then amplified and tittered to infect Sf9 cells for large-scale expression of mutants. 
The expressed proteins, secreted in the medium, were purified using a Q Sepharose Fast 
Flow column followed by a Ni2+-NTA agarose column. Protein concentrations were 




4.2.4 Choline Substrate Kinetics 
Substrate kinetics of BChEG117H and loop mutants were conducted similarly to the 
method described in section 3.2.4. Briefly, 17.5 ng of enzyme (diluted in PBS) was added 
to a 96-well place and combined with the substrate cocktail (100 µM DTNB in Tris-E 
buffer, pH 7.4) containing a range of BTChI concentrations (10, 25, 50, 75, 100, 250, 
500, 750, 1000, 2000 µM). Enzyme activity was estimated based on the rate of 
appearance of the reaction product, 2-nitro-5-thiobenzoate (ε = 14,150 M-1 cm-1) at 412 
nm in quadruplicate reactions, and was uniformly corrected for non-enzymatic substrate 
hydrolysis. Vmax and KM were determined using non-linear regression using the 
Michaelis-Menten equation. Turnover number, kcat, was calculated using the relationship 
Vmax = kcat[E], where [E] represents the concentration of BChE active sites in the reaction. 
4.2.5 Paraoxon Hydrolysis Assay 
Enzyme activity against the OP substrate paraoxon was determined using a direct 
hydrolysis assay, similar to that used by Lockridge and coworkers [14]. BChEG117H and 
loop mutant enzymes were diluted to 0.06 mg/ml using PBS. Stock paraoxon (10 mM in 
100% ethanol) was diluted on the day of assay to achieve final concentrations between 
10-500 µM containing 5% ethanol. The final reaction volume was 100 µl containing 7.5 
µl diluted enzyme, 72.5 µl 100 mM potassium phosphate buffer (pH 7.0), with the 
reaction being started by the addition of 20 µl of paraoxon. The product of paraoxon 
hydrolysis, p-nitrophenol, is monitored at 405 nm for one hour using a Spectramax M2 
microplate reader (Molecular Devices; Sunnyvale, CA) pre-heated to 37°C.  The 
extinction coefficient of p-nitrophenol (ε = 18,500 M-1 cm-1) was used to determine 
enzyme activity which was corrected for non-enzymatic hydrolysis. 
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4.2.6 Resistance to Inhibition Assay 
Prior to the reactivation assay, the sensitivity of wild-type enzyme to inhibition by 
the selected OP compounds was determined. BChE (20 ng) was pre-incubated with PO, 
DFP, or EthP (0.5 - 500 nM for all) for 20 minutes at 37℃, prior to addition of substrate 
(1 mM BTChI) for the measurement of activity as described in section 3.2.3. Enzyme 
activity was reported as percent residual activity as compared to control (no inhibitor) 
values.  
The loop-mutant enzymes’ ability to resist inhibition by OPs was conducted using 
a method derived from Wang and colleagues [314]. Based on previously determined 
protein content, working enzyme solutions were prepared prior to assay (2 µg/ml in 100 
mM potassium phosphate buffer, pH 7.0). Twenty ng of enzyme and either paraoxon (50 
µM final), diisopropylfluorophosphate (5 µM final), echothiophate (100 µM final), or 
buffer (to evaluate control enzyme activity) was pre-incubated for 10 minutes in a 96-
well plate containing buffer (100 mM potassium phosphate, pH 7.0) and DTNB (0.5 mM 
final). Following pre-incubation, 20 µl of BTChI (1 mM final) was added to begin the 
reaction. The reaction was monitored as described in section 3.2.3, and results are 
reported as percent of non-inhibited control. 
4.2.7 OP Reactivation Assay 
The rate of dephosphylation (k3) is a measure of an enzyme’s ability to reactivate 
following OP exposure and thus can be a good measure of progress in catalytic 
bioscavenger development. The k3 of BChEG117H and loop-mutants was determined 
exactly as described in Lockridge and colleagues [14]. In brief, enzyme (20 µg/ml) and 
OP (10 mM paraoxon, echothiophate, or DFP) were pre-incubated for one minute to 
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allow for complete saturation of enzyme active sites. Following incubation, a 5 µl sample 
was removed, diluted 400-fold into a cuvette containing necessary reaction elements (0.5 
mM DTNB, 1 mM BTChI, 100 mM potassium phosphate buffer, pH 7.0) and gently 
mixed. The large dilution reduces the final OP concentration to below its KM, resulting in 
rapid dissociation of non-covalently bound enzyme-OP Michaelis complexes. 
Reactivation of covalently bound enzyme was then followed at 412 nm at 37°C using a 
Spectramax M2 microplate reader (Molecular Devices; Sunnyvale, CA). As this assay is 
very time sensitive, the time between sample transfer and initiation of cuvette reading 
was kept constant (5 sec). 
4.2.8 Statistical Methods 
Differences in enzyme activity and substrate kinetics parameters with both BTChI and 
paraoxon, were evaluated using one-way ANOVA with enzyme type (i.e. BChEG117H or 
loop mutants [ENI, ENI, ENG, ENR, ENT]) as the main factor. When the concentration-
dependent inactivation of wild-type rhBChE was evaluated (i.e. IC50) the inhibitor 
concentrations (x-values) were log-transformed and the data fit to a nonlinear regression 
equation (using a variable slope model). Initial plots of enzyme reactivation were fitted 
using linear regression, constrained between 2 and 7 minutes. The difference between the 
actual versus extrapolated values between 0 and 2 minutes were then plotted on a log10 
x-axis versus time. These secondary plots were fit using a one-phase decay model for 
determination of the rate constant (under these conditions, the rate constant represents k3). 
For the resistance to inhibition and reactivation rate (k3) assays, statistical differences 
were determined using two-way ANOVA with enzyme and OP type as the main effect 
variables. In all cases, a post hoc Dunnett’s multiple comparisons test was performed to 
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determine differences among BChEG117H and the loop mutants. Statistical significance 
was defined as a p-value < 0.05 in all cases, and p-values resulting from multiple 
comparisons analysis reported in-text are multiplicity adjusted. All statistical tests were 
conducted using GraphPad Prism software (La Jolla, CA), version 6.0.  
4.3 RESULTS 
4.3.1 Molecular Dynamics Studies 
 Simulations of enzyme-substrate interactions over 200 nanoseconds were 
performed with five of the loop mutant enzymes and four OP compounds. Simulations 
were not performed with the ENP mutant due to low esteratic activity (described in 
section 4.3.2). Movies of the MD simulations have been deposited online and are 
available at: https://doi.org/10.17026/dans-xym-nu36. Figure 4-1 shows the average 
position of butyrylcholine (BCh), PO, DFP, and EthP in the active site pocket during the 
MD simulation with BChEG117H. While the choline ester substrate retained contact with 
active site residues of BChEG117H (3-4 Å), the OP compounds generally did not keep 
stable contact with active site residues. Of the OP compounds, EthP had the strongest 
interactions with the enzymes’ active site overall. In the case of PO, the ENI mutant had 
stronger interactions with the active site compared to BChEG117H. Observed interactions 
with DFP were the most unstable overall, even leaving the protein completely when 
modeled with BChEG117H and ENG, though slightly improved interactions were noted 

















Figure 4-1. Average distance of substrate molecules to the active site of BChEG117H. 
Molecular dynamics studies were performed to model the interaction of butyrylcholine, 
PO, DFP, and EthP with the active site triad of BChEG117H. The positions of the 













4.3.2 Activity of Loop Mutants with BTChI as Substrate 
The activity of BChEG117H and the BChEG117H-derived loop mutants were 
evaluated first using the choline substrate, BTChI. Figure 4-2 shows that all loop mutants 
had significantly reduced activity (62-95%) compared to BChEG117H  (F(6,28) = 606.8, p < 
0.0001). The rank order of activity of the loop mutants can be separated into three tiers, 
based on the determined 95% confidence intervals (ENP < ENI, ENA, ENR < ENG, 
ENT).  Due to its low activity, ENP was not included in further evaluations. The activity 
of the loop mutants using BTChI was further characterized using a substrate kinetics 
assay described in section 4.2.4 (Fig 4-3). Table 4-1 shows the kinetics parameters (kcat, 
KM, and kcat/KM) determined using nonlinear regression fit to the Michaelis-Menton 
equation. The turnover rate with BTChI was significantly reduced (40−84%) in all 
enzymes with loop insertions compared to BChEG117H (F5,156 = 58.06, p < 0.001). A 
significant effect was also found in KM values (F5,156 = 5.25, p = 0.0002). Post hoc 
analysis indicated that ENG (p = 0.04) and ENR (p < 0.0001) mutants had a significantly 
higher KM in comparison to BChEG117H. These parameters together as the ratio kcat/KM 
suggest that the catalytic efficiency of the loop mutants was reduced compared to 
BChEG117H. Note that the mutants were designed based on computational identification of 









Figure 4-2. Activity of BChEG117H and loop mutants with BTChI as substrate. Enzyme 
activity was determined as described in section X, using 20 ng of enzyme and 1 mM 
BTChI as the substrate. Data are reported as units of enzyme activity (defined as 
µmol/min) per milligram of enzyme (mean ± SD; n=5). Asterisks indicate a significant 








Figure 4-3. Concentration-dependent hydrolysis of BTChI by BChEG117H and loop 
mutants. Each enzyme preparation was incubated with butyrylthiocholine (10 µM - 2000 
µM) for 5 min at 37℃ and activity measured using a modified Ellman method. Data 










Table 4-1. Substrate kinetic parameters (kcat, KM, and kcat/KM) for BChEG117H and 
loop mutants. Each enzyme was incubated with BTChI (10-2000 µM) for 5 min at 37°C 
and activity measured using the photometric method. Data were analyzed using the 
Michaelis-Menten equation and represent mean values with 95% confidence intervals in 
parentheses (n=3).  
 













































4.3.3 Resistance to Inhibition 
Prior to the evaluation of loop mutant enzymes against OP inhibitors, we first 
measured the inhibitory potency of the selected inhibitors (PO, DFP, EthP) using wild-
type rhBChE to select a starting point for values for use in subsequent assays (Fig. 4-4). 
The determined IC50 values were 23.3 (95% confidence interval [CI] = 15.2 - 35.5), 9.4 
(CI = 1.2 - 71.8), and 55.4 (CI = 45.0 - 68.2) for PO, DFP, and EthP, respectively. An 
enzyme’s ability to resist inhibition by a high OP concentration can be used as a 
preliminary screening assay for OP hydrolyzing ability [314]. We initially defined a high 
concentration as one which can inhibit >99% of the wild-type enzyme (PO and EthP = 
500 nM, DFP = 50 nM), and tested this against BChEG117H and the loop mutant enzymes 
(Fig. 4-5A). The results showed that the BChEG117H  retained 100% of the control activity 
(mean[CI] = 105 [96 - 114]), and the loop mutant enzymes were inhibited by no more 
than 10%. In order to detect differences between the enzyme types, it was necessary to 
find OP concentrations which are able to partially inhibit BChEG117H. Therefore, we 
repeated the resistance to inhibition assay with inhibitor concentrations increased 10-fold, 
though BChEG117H remained mostly resistant to inhibition (mean[CI] = 97.8 [84.1 - 
111.4]) (Fig. 4-5B). Interestingly, the loop mutants retained complete activity as well. 
The final selected OP concentrations (PO = 50 µM, DFP = 5 µM, EthP = 100 µM) 
resulted in inhibition of BChEG117H between 10-40%. 
 Figure 4-6 shows the ability of BChEG117H and loop mutants to resist inhibition by 
a high concentration of OP following a 10-minute incubation period. Under these 
conditions, there was a significant main effect of inhibitor-type (F(2, 36) = 594.7, p < 
0.0001) and enzyme type (F(5, 36) = 2.537, p = 0.046), as well as a significant interaction 
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(F(10, 36) = 7.401, p < 0.0001). With paraoxon, BChEG117H was somewhat more resistant to 
inhibition compared to all five loop mutants studied, i.e., it retained 57% of its activity 
following paraoxon exposure while loop-mutants retained only 31−44% of pre-exposure 
activity. In contrast, when DFP was used as the inhibitor the loop mutants were generally 
more resistant to inhibition. Specifically, ENI, ENA, ENG, and ENR mutants retained 
nearly full activity (96−100%) following DFP exposure, which was statistically 
significant (p < 0.05) compared to the activity retained with BChEG117H (82%). A similar 
finding was noted following exposure to EthP, with two loop mutants (ENA and ENR) 
being more resistant to inhibition than BChEG117H (p = 0.03 and 0.0007, respectively).  A 

















Figure 4-4. BChE sensitivity to inhibition by PO, DFP, and EthP. BChE (20 ng) was pre-
incubated with PO, DFP, or EthP (0.5 - 500 nM for all) for 20 minutes at 37℃, prior to 
addition of substrate (1 mM BTChI) and measuring residual activity. Data represent mean 
values ± SD (n=2). The determined IC50 values were 23.2 nM, 9.4 nM, and 55.4 nM for 









Figure 4-5. Preliminary range finding assays for resistance to inhibition of BChEG117H and 
loop mutants. All enzymes were exposed to paraoxon, DFP, or EthP for 10 minutes 
followed by colorimetric BChE activity determination using BTChI as substrate (1 mM 
final). Inhibitor concentrations in Panel A (PO = 500 nM, DFP = 50 nM, EthP = 500 nM) 
represent determined IC99 values, while concentrations in Panel B have been increased by 














Figure 4-6. Comparative resistance to inhibition of BChEG117H and loop-mutants 
following a 10-min exposure to paraoxon (50 µM final), DFP (5 µM final) or EthP (100 
µM final). Data are reported as percent of control (no inhibitor) values (mean ± SD of 













4.3.4 Reactivation of Loop Mutants 
While the resistance to inhibition screening assay suggested that the loop 
insertions may alter the interaction of the mutant enzymes and inhibitors, it cannot 
determine the mechanism of resistance. Possible interpretations include changes in 
binding affinity for the inhibitor and/or increased reactivation rate following binding. 
Therefore, we next conducted an assay to determine the reactivation rate of BChEG117H 
and loop mutants against OP compounds in isolation. The rationale for this assay includes 
an initial incubation step with an excess of an OP compound in order to putatively 
occupy all active sites of the enzyme being tested followed by a marked (400-fold) 
dilution to dissociate any reversible enzyme-OP Michaelis complexes. Thus, measuring 
the rate of recovery of enzyme activity under these conditions reflects the rate of 
dephosphylation.  The reactivation rate (k3) was calculated by plotting the difference 
between observed and estimated values versus time during the recovery period, as 
described previously by Lockridge and coworkers [14]. Note that the reported k3 values 
in cases where recovery did not achieve 100% of baseline were corrected using the 
approach of Hovanec and colleagues [315].  
  Figures 4-7, 4-8, and 4-9 show the raw reactivation data for each enzyme against 
paraoxon, DFP, and echothiophate, respectively. Baseline (100%) activity for each 
enzyme was estimated using enzyme without inhibitor, and while enzymes which were 
incubated with PO and EthP reached the baseline activity during the 7-minute 
measurement window, the DFP exposed enzymes did not. When BChEG117H was 
incubated with DFP, the maximum hydrolysis rate achieved was only 67% compared to 
baseline (Table 4-2). The reactivation achieved by the loop mutant enzymes was 
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proportionally more (between 72-90%), particularly with the ENR loop mutant which 
reactivated completely (as determined by an overlapping 95% confidence interval with 
the baseline activity). The k3 values of BChEG117H with echothiophate (mean[CI] = 1.28 
min-1 [1.21 - 1.35] ) and paraoxon (mean[CI] = 1.27 min-1 [1.06 - 1.49]) were relatively 
similar to those reported previously [14]. To our knowledge, the reactivation rate of 
BChEG117H with DFP has not been previously reported. Two-way ANOVA determined 
that there was a significant main effect of enzyme type (F(5, 807) = 8.335, p < 0.0001) as 
well as a significant interaction (F(10, 807) = 3.619, p < 0.0001). Post hoc multiple 
comparisons determined that when paraoxon was used, the ENA loop mutant showed a 
slight but significant increase in k3 (p = 0.01) as compared to BChEG117H (Figure 25). In 
contrast, when DFP was used, the k3 of the ENI (p = 0.0006) and ENR (p = 0.006) loop 
mutants was significantly decreased as compared to BChEG117H.  There were no 














Figure 4-7. Recovery of BChEG117H and loop mutant activity following exposure to PO. 
Enzymes were incubated with 10 mM PO for 1 minute prior to a 400-fold dilution into 
the substrate cocktail (containing 1 mM BTChI substrate, final) as described in section 
4.2.7. The dotted line represents the mean value of the raw data points (n=3), while the 
solid line is the linear regression fit (between 2-7 minutes). The standard deviation of the 
raw data points is represented as the shaded grey area. Note that while the x-axes are on 









Figure 4-8. Recovery of BChEG117H and loop mutant activity following exposure to DFP. 
Enzymes were incubated with 10 mM DFP for 1 minute prior to a 400-fold dilution into 
the substrate cocktail (containing 1 mM BTChI substrate, final) as described in section 
4.2.7. The dotted line represents the mean value of the raw data points (n=3), while the 
solid line is the linear regression fit (between 2-7 minutes). The standard deviation of the 
raw data points is represented as the shaded grey area. Note that while the x-axes are on 








Figure 4-9. Recovery of BChEG117H and loop mutant activity following exposure to EthP. 
Enzymes were incubated with 10 mM EthP for 1 minute prior to a 400-fold dilution into 
the substrate cocktail (containing 1 mM BTChI substrate, final) as described in section 
4.2.7. The dotted line represents the mean value of the raw data points (n=3), while the 
solid line is the linear regression fit (between 2-7 minutes). The standard deviation of the 
raw data points is represented as the shaded grey area. Note that while the x-axes are on 








Table 4-2. Enzyme reactivation of BChEG117H and loop mutants with DFP. Enzymes were 
incubated with 10 mM DFP for 1 minute followed by a 400-fold dilution prior to 
measurement of activity using BTChI. Values are reported as mean and 95% confidence 
intervals, when appropriate (n=3). 
 
a Corrected values were determined using the method described by Hovanec and 
colleagues, by multiplying the observed k3 values by the determined percent reactivation 
values and dividing by 100 [315].  
b A corrected k3 value was not calculated for ENR as the 95% confidence intervals for the 








































































Figure 4-10. Reactivation rates (k3) of BChEG117H and loop mutants following exposure to 
10 mM of an OP compound (PO, DFP or EthP). Enzyme was allowed to react with the 
inhibitor for one minute and then diluted 400-fold into a solution containing substrate 
(BTChI, 1 mM).  The data are reported as mean with 95% confidence interval bars (n=3). 
In the case of DFP, 100% reactivation was not achieved, thus reported k3 values have 
been corrected based on Hovanec et al [315]. Asterisks indicate a significant difference 








4.3.5 Paraoxon Hydrolysis 
As a statistically significant difference was noted with enzyme reactivation assays 
with paraoxon, we next conducted a direct hydrolysis assay using paraoxon as the 
substrate. The substrate kinetics assay suggested that all loop mutants had altered 
catalytic activity as compared to BChEG117H (F(10,148) = 46.76, p < 0.0001)(Fig. 4-11).  
Table 4-3 compares substrate kinetics parameters among the different enzymes. 
Significant differences were detected in both kcat (F(5,148) = 29.46) and KM (F(5,148) = 
5.735, p < 0.0001) values. Post hoc multiple comparisons indicated that kcat was 
significantly lower than BChEG117H in all loop mutant enzymes (p < 0.0001 for all), and 
KM was significantly lower in the ENA (p = .0005), ENG (p = 0.001), and ENT (p = 
0.0009) mutants. The loop mutants ENA, ENG, and ENT showed a trend toward higher 
catalytic efficiency (kcat/KM) compared to BChEG117H, but this appeared driven by the 
changes in KM and not catalytic activity. Changes in substrate binding affinity could be 













Figure 4-11. Concentration-dependent hydrolysis of PO by BChEG117H and loop mutants. 
Each enzyme preparation was incubated with paraoxon (10 µM - 500 µM) for 5 min at 
37℃ and activity quantified by the measurement of the hydrolysis product, p-nitrophenol 










Table 4-3. Comparison of the substrate kinetics parameters of BChEG117H and loop 
mutants using PO. Kinetic analysis was determined using non-linear regression with the 
classic Michaelis-Menten equation. Mean values are reported with 95% confidence 
intervals in parentheses.  
 
















































 The use of BChE as a prophylactic agent is hindered by its stoichiometric 
interaction with OP toxicants. From a functional standpoint, OP compounds irreversibly 
bind to ChEs, but molecularly, the interaction proceeds similar to that of substrates. The 
most pronounced difference between the different interactions is in the reactivation (k3) 
step (refer to Fig. 2-2). Therefore, it is conceivable that re-engineering of BChE could 
increase the rate of reactivation, resulting in an efficient catalyst of OP compounds. 
While it is well established that enzymes’ catalytic machinery is dependent on protein 
structural characteristics, recent research suggests that the dynamic motion of the protein 
is also important for catalysis [316]. Moreover, it has been suggested that enzyme 
structure and dynamics of certain surface loop regions enable thermodynamical coupling 
between the enzyme surface and active site residues by collecting energy from 
interactions with solvent molecules and relaying it to the active site through a network of 
residues. The current study sought to apply these principles to BChEG117H, a previously-
developed mutant which can slowly hydrolyze OP compounds, to better understand the 
role of surface peptide networks in catalysis, and study the structure-dynamics-activity 
relationships in catalytic degradation of OP compounds. Initial molecular dynamics 
simulations identified a dynamic surface loop on BChEG117H (278−285), and we 
hypothesized that a 3-residue insertion into this region would increase energy transfer to 
the active site, resulting in an increased rate of catalysis. To evaluate the effect of these 
insertions, we modeled the enzyme-substrate interactions in the active site and measured 




 We first studied the catalytic interaction of the engineered loop mutants with 
BTChI. As native BChE is operating near the diffusion-limited rate with choline 
substrates, it is expected that the introducing mutations would if anything result in a 
decreased catalytic rate. This effect was observed with BChEG117H as compared to the 
wild-type enzyme [14]. We found that all of the produced loop mutants had a 
significantly reduced catalytic efficiency (kcat/KM) compared to BChEG117H. Our data also 
suggested that binding of the substrate in the loop mutants was reduced relative to 
BChEG117H. These findings suggest that the introduced changes in the surface peptide 
network were indeed influencing physiochemical interactions in the active site region, 
albeit in a negative manner relative to catalytic activity with BTChI.  
 We conducted two assays to elucidate the enzymes’ interactions with the three OP 
compounds. The relative resistance to inhibition by a high concentration of PO, DFP, or 
EthP provided an initial perspective on the effect of our surface loop mutations. It should 
be noted that with this assay, the mechanism of resistance cannot be fully appreciated, but 
a change in resistance to inhibition may reflect a change in catalytic activity or substrate 
binding. When DFP and EthP were used, the loop mutants were relatively more resistant 
to inhibition compared to BChEG117H. The resistance found with ENA and ENR was 
statistically significant with both OP compounds. In contrast, all loop mutants were 
significantly less resistant to inhibition by paraoxon compared to BChEG117H, suggesting 
an important structure-dynamics-activity relationship. While paraoxon has the classical 
organophosphate structure (i.e. phosphate ester), DFP is a phosphorofluoridate and EthP 
is a phosphorothioate [317]. To further clarify the mechanism of altered interactions 
between the enzyme and substrates, we measured enzyme reactivation, which is 
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relatively unaffected by changes in substrate binding. Interestingly, the ENA mutant had 
a significantly increased reactivation rate compared to BChEG117H with paraoxon. 
However, we did not detect this effect in the direct paraoxon hydrolysis assay, where we 
found a significant decrease in the enzyme’s turnover rate (kcat). Taken together, these 
results suggested that the decreased KM with paraoxon (seen in the direct hydrolysis assay 
and supported by the resistance to inhibition assay) had more impact on the enzyme’s 
apparent efficiency than the small increase in reactivation rate. Reactivation data with 
DFP and EthP did not show significant increases in k3, suggesting that the noted increase 
in loop mutant resistance to inhibition is also a reflection of altered binding. A direct 
hydrolysis assay with DFP and EthP may confirm this presumption.  
  Molecular dynamics simulations of BChEG117H and the engineered loop mutants 
with the choline ester substrate butyrylcholine and selected OP compounds provided 
insights into the observed experimental findings. While BCh had strong interactions with 
all enzymes tested, the OP compounds showed mostly weak interactions. The OP 
compounds frequently lost contact with the active site pocket in less than 50 
nanoseconds. From this, it can be inferred that the enzyme has limited time for effective 
hydrolysis [242]. Interestingly, in some cases, loop mutations appeared to slightly 
improve the stability of PO and EthP in the active site pocket of BChEG117H, through an 
unknown mechanism.  
In conclusion, the results confirmed that surface peptide networks identified on 
this enzyme by molecular simulations can influence substrate-active site interactions and 
be potentially used to enhance the hydrolysis of catalytic bioscavengers. In particular, we 
observed a slight but significant increase in the dephosphylation rate constant with 
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paraoxon with one (ENA) loop mutant. While these changes were subtle, our data 
suggest that increasing the interaction of identified hypermobile surface loops with the 
solvent may potentially yield improved catalytic interactions between OP-hydrolyzing 
enzymes and their substrates. It is likely that significant improvements in the active site 
stability of OP compounds with BChE are necessary for significant improvement of 
catalytic rate. Due to this, the approach of targeting of surface loop dynamics may be 
better suited to native OP hydrolases (e.g., paraoxonase, phosphotriesterase) with higher 
intrinsic catalytic activity against OP compounds (and, presumably, more stable active 
site interactions). Understanding how surface loop networks and their dynamics 
contribute to catalysis may lead to further development of more effective catalytic 







IN VITRO AND IN VIVO EVALUATION OF 
TOXICOKINETICS/TOXICODYNAMICS OF FREE PYRIDOSTIGMINE AND 
PYRIDOSTIGMINE IN NANOCRYSTALLINE CELLULOSE HYDROGELS 
 
5.1 INTRODUCTION 
Pyridostigmine bromide is currently the only drug available for military use as a 
prophylactic against nerve agent exposure. PB is formulated for prophylactic use as 30 
mg tablets. These tablets require refrigerated storage and must be discarded three months 
after distribution. Following oral dosing with these tablets, PB reaches its maximal blood 
concentration at two hours, and the half-life of PB is approximately three hours [318]. As 
a result, soldiers are required to take a dose every eight hours to achieve and retain 
protection (considered to be 20-40% blood AChE inhibition). In a retrospective study of 
Gulf War veterans, 61% of soldiers reported taking fewer than the recommended three 
pills daily [319]. Formulations which extend the pharmacokinetics of PB would decrease 
the recommended dosing schedule, thereby improving logistics and potentially increasing 
compliance. 
Hydrogels are a type of drug delivery system constructed from crosslinked 
polymer chains, which release drugs via diffusion, controlled by the mesh/pore size of the 
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polymer network [320]. Nanocrystalline cellulose (NCC) is a material produced from 
cellulose fibers which can be used to create hydrogels for improved drug delivery [321]. 
In vitro evaluation of BSA-loaded CNC showed a biphasic release - a “burst” phase 
during the initial 8 hours, followed by gradual release up to 48 hours. By 48 hours, 90-
100% of the BSA had been released from the hydrogel [322]. NCC is essentially non-
toxic by oral delivery and can be produced renewably and inexpensively, making it an 
attractive drug delivery vehicle [321, 323].  
 The major goal of Aim 3 was to characterize how NCC-PB formulations alter the 
pharmacodynamic and pharmacokinetic interaction of PB and AChE. We hypothesized 
that NCC-PB hydrogel formulations would extend the time course of AChE inhibition in 
both in vitro and in vivo assays. Preparation of nanocrystalline cellulose is frequently 
conducted via sulfuric acid hydrolysis of cellulose fibers; however, another method of 
hydrolysis (TEMPO-oxidation) results in NCC which has carboxylic acid groups on its 
surface amenable to functionalization. Three NCC-PB hydrogel formulations were 
prepared using the “normal” method, wherein the crosslinking conditions were altered, 
and lyophilized prior to use. A final NCC-PB formulation was prepared using the 
TEMPO-oxidation methods to test the effect of differing surface chemistries. Using the 
rehydrated NCC hydrogels, we compared the time course of in vitro AChE inhibition 
during incubation with NCC-PB and free PB using mouse blood and intestinal 
homogenate. We then evaluated the comparative effects of one NCC-PB hydrogel 





5.2 MATERIALS AND METHODS 
5.2.1 Chemicals 
Nanocrystalline cellulose hydrogel-encapsulated PB was produced by InnoSense, 
LLC (Torrance, CA). NCC starting material was obtained from CelluForce (Montreal, 
QC, CA). Three hydrogel formulations were prepared using nanocrystalline cellulose 
sulfate particles which were crosslinked with epichlorohydrin for one (NCC-PB1), or ten 
(NCC-PB10) minutes prior to addition of PB into the mixture. The third formulation 
added PB immediately following addition of the crosslinking agent (NCC-PB0). All other 
preparation details were kept consistent. A fourth hydrogel formulation (TEMPO-PB) 
utilized a different form of cellulose, which was prepared using 2,2,6,6-
tetramethylpiperidine-1-oxyl radical (TEMPO). Due to the altered surface chemistry of 
the TEMPO-oxidized gels, calcium chloride dihydrate was added to form metal-ion 
complexes (as opposed to chemical crosslinking by epichlorohydrin).  
 Tissue sources of ChE (small intestine and whole blood from CD1 mice) were 
obtained from Charles-River (Wilmington, MA). Upon receipt, tissues were 
homogenized or diluted in PBS and immediately frozen at -80℃ until use. Free 
pyridostigmine bromide (3-(dimethylaminocarbonyloxy)-1-methylpyridinium bromine; 
PB) (100% purity by HPLC) used in in vitro and in vivo studies was purchased from 
Sigma-Aldrich (St. Louis, MO) and kept desiccated under nitrogen at room temperature 
until use. [3H]Acetylcholine iodide (specific activity about 65.5 mCi/mmol) was 
purchased from Perkin-Elmer (Waltham, MA). Certified ACS grade toluene and iso-amyl 
alcohol were purchased from Fisher Scientific (Waltham, MA). POPOP (1,4-Bis[5-
phenyl-2-oxazolyl] benzene), PPO (2,5-diphenyloxazole), potassium phosphate, and 
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other remaining chemicals and reagents were purchased from Sigma-Aldrich (St. Louis, 
MO).   
5.2.2 Animals 
All studies were conducted using 6-week-old, male, CD1 mice (35-40 g) 
purchased from Charles River and acclimated for at least one week prior to study 
initiation. Mice were kept in shoebox cages under a 12-12-hour light-dark cycle with ad 
libitum access to water and standard chow. All procedures were approved by Oklahoma 
State University’s Institutional Animal Care and Use Committee.  
5.2.3 Radiometric Cholinesterase Assay 
 In some cases, acetylcholinesterase activity was measured radiometrically using 
the method of Johnson and Russell [324]. This assay avoids complications regarding 
quantitation of cholinesterase activity in blood samples (which can be difficult using the 
photometric method), and it also allows use of highly concentrated tissue samples not 
possible with the photometric method (due to turbidity interference). The enzyme source 
(e.g. mouse blood, tissue homogenate) was diluted using phosphate buffered saline (PBS; 
10 mM phosphate buffer containing 154 mM NaCl, pH 7.4) before use. Twenty μl of the 
enzyme source was added to 60 μl of potassium phosphate buffer (50 mM, pH 7.0), and 
the reaction started by addition of 20 μl [3H]acetylcholine (1 mM final concentration). 
Reactions were allowed to proceed at 37°C until termination by addition of an acidified 
stop solution (1 M chloroacetic acid, 0.5 M NaOH, and 2 M NaCl) followed by extensive 
vortexing. A hydrophobic scintillation cocktail (0.5% PPO/0.03% POPOP/10% iso-amyl 
alcohol in toluene) was then added and the product ([3H]acetic acid) was separated by 
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liquid-liquid exchange and then counted in a scintillation counter (Perkin Elmer Tri-Carb 
2810 TR; 61% efficiency). 
5.2.4 In Vitro Time Course of ChE Inhibition 
Mouse blood or homogenized small intestine was diluted 1:10 in PBS to be used 
as the tissue/enzyme source. A pyridostigmine bromide solution (3 μM for whole blood; 6 
μM for intestinal homogenate) was prepared in PBS in advance and kept on ice until use. 
Just before the assay, the contents of one vial containing lyophilized NCC-PB gel 
(provided by InnoSense, LLC) was ground using a small mortar and pestle, the powder 
transferred to a polypropylene tube and then rehydrated with 3 ml of PBS. The solution 
(putatively 5.745 mM pyridostigmine) was vortexed to ensure an even suspension prior 
to rapid serial dilution to obtain a 3 or 6 μM working concentration of PB in NCC-PB0, 
NCC-PB1, NCC-PB10 and TEMPO-PB. PBS, diluted pyridostigmine, or the gel working 
reagent (250 μl each) was then added to an equal volume of the diluted blood or intestinal 
sample (500 μl final volume). The vials were vortexed and then placed into a 37°C water 
bath with mild shaking. At specified time points (10, 20, 40, and 80 minutes), aliquots (20 
μl) of the mixtures were withdrawn and assayed for AChE activity using the radiometric 
method described in section 5.2.3. All reactions were corrected for non-enzymatic 
substrate hydrolysis. Preliminary assays were conducted to determine the appropriate 
blood dilution and incubation time to capture a linear rate of substrate hydrolysis. 
5.2.5 In Vivo Pharmacodynamic Evaluation 
To evaluate comparative time-dependent inhibition of AChE by free PB and 
NCC-PB0, the maximum tolerated dose (MTD) was determined first. MTDs were 
estimated using the up-and-down method [325], which involved treating one to three 
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mice and observing cholinergic toxicity and lethality for 24 hours. If the treated animal(s) 
survived 24 hours, the previous dose was multiplied by a factor of 1.3. If the animal(s) 
did not survive 24 hours, the previous dose was divided by 1.3.  This continued until an 
MTD estimate was determined. Functional signs were recorded and ranked according to 
the following scale: 0 = no signs, 1 = very slight signs such as possible fasciculations and 
piloerection, 2 = slight toxicity including fasciculations, salivation or lacrimation (i.e. 
SLUD signs), 3 = moderate signs including head and neck area tremors, tail “twitching” 
and more obvious fasciculations and/or SLUD signs, 4 = severe, notable whole body 
tremors, prostrate/reduced ambulation, extensive fasciculations and/or SLUD signs, 
occasional choreatic movements, and 5 = death.  
 Following MTD determination, the selected doses were utilized for subsequent 
time course studies. Animals were divided into two groups, free PB and NCC-PB0 (n = 
5-6/group). Prior to dosing, baseline cholinesterase activity was determined for each 
animal by collecting a small blood sample (5 μl) via a tail snip procedure. A solution of 
free pyridostigmine bromide (13.33 mg/kg) was made in PBS and used for all PB dosing, 
adjusting the dosing volume accordingly for each dose. Contents of a vial of lyophilized 
NCC-PB0 gel (65 mg wet weight) containing 40 ± 5 mg pyridostigmine was 
homogenized using a small mortar and pestle and then rehydrated by adding 3 ml PBS to 
obtain a putative PB concentration of 13.33 mg/ml.  Free PB and NCC-PB0 gel were 
administered by oral gavage, making sure that gavage treatments were completed as soon 
as possible after gel rehydration to minimize pyridostigmine release prior to dosing. 
Functional signs of cholinergic toxicity were recorded and ranked 1-5 according to the 
severity and presence of muscle fasciculations, tremors, and SLUD signs (i.e. salivation, 
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lacrimation, urination, defecation). At specified time points (45, 90, 180, 270, 380, 720, 
1080, and 1440 minutes) small blood samples were collected from the tail to assay for 
cholinesterase activity as described in section 5.2.3. 
5.2.6 Statistical Methods 
For in vitro studies, data from three independent samples were normalized based 
on vehicle controls (100% activity). In both cases (in vitro and in vivo) ChE inhibition 
data were analyzed using a two-way repeated measures ANOVA, with time and 
formulation type as the main factors. When appropriate, t-tests were also used for 
pairwise comparison (noted in-text). If warranted, a post hoc Dunnett’s multiple 
comparison test was used to determine statistical significance between conditions. 
Statistical significance was defined as a p-value < 0.05 in all cases, and p-values resulting 
from multiple comparisons analysis reported in-text are multiplicity adjusted. All 
statistical tests were conducted using GraphPad Prism software (La Jolla, CA), version 
6.0.    
5.3 RESULTS 
5.3.1 In Vitro Evaluation of NCC-PB 
Four nanocrystalline cellulose pyridostigmine formulations – NCC-PB0, NCC-
PB1, NCC-PB10, and TEMPO-PB –  were compared against free PB for their in vitro 
time-dependent anticholinesterase activity. A mixture of the PB gel and either small 
intestinal homogenate or whole blood was vortexed and incubated at 37°C. Aliquots were 
removed at specified time points for measurement of residual ChE activity (Figs. 5-1 and 
5-2). In each case, the ChE inhibition progressively increased until about 1-2 hours, at 
which point a plateau was achieved, suggesting maximal ChE inhibition. A slight 
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increase in activity was noted at later time points, likely due to reactivation of PB-
inhibited enzyme molecules.  
Figure 5-3 shows the comparison of intestinal ChE inhibition by NCC-PB0, -PB1, 
and -PB10 at each time point. Two-way ANOVA of the intestinal cholinesterase data 
revealed a significant main effect of PB gel formulations (F(3, 8) = 7.176, p = 0.012) as 
well as a significant interaction (F(15, 40) = 1.953, p = 0.046). Post hoc multiple 
comparisons showed that the NCC-PB0 formulation was significantly different from free 
PB at the 10 (p = 0.0001), 30 (p < 0.0001), and 60 (p = 0.0007) minute time points. The 
NCC-PB10 formulation was significantly different from free PB at the 10 (p = 0.02) and 
30 (p = 0.02) minute time points, while the NCC-PB1 formulation was not different at 
any time point. Figure 5-4 shows the comparison of each PB gel formulation’s ability to 
inhibit blood ChE at each time point. When whole blood was used as the ChE source, the 
two-way ANOVA showed a similar main effect of PB gel formulations (F(4,13) = 62.67, p 
< 0.0001) and a significant interaction (F(20,65) = 3.072, p = 0.0003). The NCC-PB0 gel 
formulation was significantly different from free PB at the 10 (p = 0.01) and 30 (p = 
0.04) minute time points. The TEMPO-PB gel was significantly different from free PB at 
all tested time points (p < 0.0001 in all cases). No significant differences were noted with 
the NCC-PB1 or -PB10 formulations.  
Interestingly, the TEMPO gel formulation showed a higher plateau (28% activity 
remaining) compared to free PB (12% activity remaining) during the eight-hour 
incubation (F(4, 118) = 56.36; p < 0.0001). Therefore, an extra time point at 24 hours was 
collected from the TEMPO gels and free PB (Fig. 5-5). The results from this incubation 
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showed that the residual activity remained relatively consistent until 24 hours, which was 


















Figure 5-1. In vitro time course of intestinal ChE inhibition by PB or NCC-PB. Free PB 
or nanocrystalline cellulose formulated PB (NCC-PB0, NCC-PB1, NCC-PB10) (3 µM 
final) were incubated with intestinal homogenate (1:10 dilution) at 37℃ with gentle 
shaking. At specified time points (10-480 min), 20 µl aliquots were removed and assayed 
for cholinesterase activity with [3H] acetylcholine as described in section 5.2.3. Data are 
reported as percent of contemporaneous controls (no PB) and represent three independent 








Figure 5-2. In vitro time course of whole blood ChE inhibition by PB or NCC-PB. Free 
PB or nanocrystalline cellulose formulated PB (NCC-PB0, NCC-PB1, NCC-PB10, 
TEMPO-PB) (1.5 µM final) was incubated with whole blood (1:10 dilution) at 37℃ with 
gentle shaking. At specified time points (10-480 min), 20 µl aliquots were removed and 
assayed for cholinesterase activity with [3H] acetylcholine as described in section 5.2.3. 
Data are reported as percent of contemporaneous controls (no PB) and represent three 








Figure 5-3. Comparison of intestinal ChE inhibition by PB or NCC-PB at selected time 
points. Free PB or nanocrystalline cellulose formulated PB (NCC-PB0, NCC-PB1, NCC-
PB10) (3 µM final) was incubated with intestinal homogenate (1:10 dilution) at 37℃ 
with gentle shaking. At specified time points (10-480 min), 20 µl aliquots were removed 
and assayed for cholinesterase activity with [3H] acetylcholine as described in section 
5.2.3. Data are reported as percent of contemporaneous controls (no PB) and represent 
three independent replicates (mean ± SD). Asterisks indicate a significant difference 







Figure 5-4. Comparison of whole blood ChE inhibition by PB NCC- PB at selected time 
points. Free PB or nanocrystalline cellulose formulated PB (NCC-PB0, NCC-PB1, NCC-
PB10, TEMPO-PB) (1.5 µM final) was incubated with intestinal homogenate (1:10 
dilution) at 37℃ with gentle shaking. At specified time points (10-480 min), 20 µl 
aliquots were removed and assayed for cholinesterase activity with [3H] acetylcholine as 
described in section 5.2.3. Data are reported as percent of contemporaneous controls (no 
PB) and represent three independent replicates (mean ± SD). Asterisks indicate a 







Figure 5-5. Comparison of whole blood ChE inhibition by PB or TEMPO-PB gel at 24 
hours. Free PB or TEMPO-PB gel (1.5 µM final) was incubated with intestinal 
homogenate (1:10 dilution) at 37℃ with gentle shaking. After 24 hours of incubation, a 
20 µl aliquot was removed and assayed for cholinesterase activity with [3H] acetylcholine 
as described in section 5.2.3. Data are reported as percent of contemporaneous controls 










5.3.2 In Vivo Evaluation of NCC-PB0 
Prior to collecting cholinesterase inhibition data, we determined the maximum 
tolerated dose (MTD) of free PB and NCC-PB0 in CD1 mice based on functional signs 
data. We first treated one mouse with 112.7 mg/kg of free pyridostigmine, which caused 
severe signs and death within one minute. Due to the rapid, lethal reaction, we decreased 
the next dose by three “steps” (each step decreases the previous dose by a factor of 1.3) to 
51.3 mg/kg. This dose resulted in a steady increase in signs until 60 minutes at which 
point death occurred. A dose of 39.5 mg/kg also resulted in death, though the animal 
survived until 4.5 hours. We decreased the dose to 20 mg/kg (between 2 and 3 “steps”), 
which caused moderate toxicity but not lethality. Therefore, the MTD for free PB was 
operationally defined as 20 mg/kg. For NCC-PB0, our first treatment dose was 39.5 
which elicited moderate signs of toxicity but no lethality. The dose was increased to 51.3 
mg/kg which also did not result in lethality. The next dose, 66.7 mg/kg, caused a steady 
increase in toxicity until death occurred around 4.5 hours. Therefore, the MTD for NCC-
PB0 was operationally defined as 51.3 mg/kg. Figure 5-6 shows the functional signs data 
over time with free PB and NCC-PB0 animals.  
 Following the MTD studies, we treated a small group of animals (2-3/group) with 
half of the MTD dose (i.e. 10 mg/kg for free PB and 25.7 mg/kg for NCC-PB0), aiming 
to inhibit a non-lethal but substantial amount of ChE activity. A baseline blood sample 
was taken from mice prior to dosing, and then subsequent blood samples were taken 
between 45- and 360-minutes post-dosing. Figure 5-7 shows the time course of inhibition 
for free PB and NCC-PB0 (0.5 MTD). During this study, functional signs and some 
lethality (one NCC-PB0 animal) were noted; therefore, the next time course study was 
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conducted using a lower dose (0.3 x MTD) (Fig. 5-8). Analysis using two-way ANOVA 
did not identify a significant main effect of formulation type (i.e. free PB versus NCC-
PB0)(p=0.14). While the 6 mg/kg dose of free PB did not cause any functional signs of 
toxicity, the 15 mg/kg dose of NCC-PB0 resulted in cholinergic signs and lethality in two 
animals.  
 Due to the toxicity noted in NCC-PB0 treated animals at 0.5 and 0.3 x MTD, we 
compared the cholinesterase inhibition caused by equivalent doses (6 mg/kg), and 
followed the inhibition to 24 hours (Fig 5-9). No signs of toxicity were noted in either 
group at the 6 mg/kg dosing level, and no significant weight loss occurred over 24 hours 
(Fig. 5-10). Similar to previous doses, we observed an apparent burst release with both 
free PB and NCC-PB0 followed by slightly extended ChE inhibition. However, these 
differences failed to reach significance (p=0.07). If the initial absorption phase (0-180 
min) is excluded from the analysis, however, there was a significant effect of formulation 
at the later time points (p=0.01). Pairwise comparisons of the elimination-only data 
identified a significant difference between PB and NCC-PB0 at the 380-minute timepoint 
(p=0.03). The area under the curve (AUC) is a measure of bioavailability. The AUC was 
17,301 (CI = 11,623 - 22, 979) for free PB and 28,584 (CI = 17,600 - 39,569) for NCC-









Figure 5-6. Comparison of acute toxicity following treatment with PB or NCC-PB0. CD1 
mice were treated with free PB (20, 39.5, and 51.3 mg/kg, po; Panel A) or NCC-PB0 
(39.5, 51.3 and 66.7 mg/kg, po; Panel B). Free PB was also given at 112.7 mg/kg, which 
led to severe signs of toxicity and death within one minute (data not plotted). Each line 















Figure 5-7. Comparison of whole blood ChE inhibition following in vivo exposure to 0.5 
MTD of PB or NCC-PB0. CD1 mice were given free PB (10 mg/kg, po) or NCC-PB0 
(25.7 mg/kg, po), which preliminary assays defined as the 0.5 maximum tolerated dose 
level (MTD). A small sample of whole blood was collected from mice at each time point 
from the tail tip, and the ChE activity was immediately measured using the radiometric 









Figure 5-8. Comparison of whole blood ChE inhibition following in vivo exposure to 0.3 
MTD of PB or NCC-PB0. CD1 mice were given free PB (6 mg/kg, po) or NCC-PB0 (15 
mg/kg, po), which preliminary assays defined as the 0.3 maximum tolerated dose level 
(MTD). A small sample of whole blood was collected from mice at each time point from 
the tail tip, and the ChE activity was immediately measured using the radiometric method 









Figure 5-9. Twenty-four-hour time course of ChE inhibition following oral PB or NCC-
PB0. CD1 mice were given free PB or NCC-PB0 (6 mg/kg, po). A small sample of whole 
blood (5-10 µl) was collected from mice at each time point from the tail tip, and the ChE 
activity was immediately measured using the radiometric method described in section 











Figure 5-10. Twenty-four-hour body weight comparison of animals treated with PB or 
NCC-PB0.  CD1 mice were given free PB or NCC-PB0 (6 mg/kg, po). All animals were 
weighed prior to dosing, and 24-hours later, the body weights were recorded again for 
comparison. Animals had free access to food and water following treatment. Data are 












Inhibitor-based prophylactics like pyridostigmine bromide have been available for 
military use since the 1990’s. While enzyme-based prophylactics may be on the horizon, 
improved PB formulations could likely be implemented more quickly and would remain 
an inexpensive alternative to biological prophylactics. The current PB tablet formulation 
must be taken every 8 hours to retain the recommended 20-40% ChE inhibition levels. 
Improved pharmacokinetics of PB release and elimination would allow for sustained 
inhibition and thus an improved dosing schedule. PB formulated within nanocrystalline 
cellulose hydrogels may provide a mechanism for improved drug release. The goal of this 
study was to evaluate several NCC-PB formulations (NCC-PB0, NCC-PB10, NCC-PB1, 
and TEMPO-PB) based on in vitro ChE inhibition. One formulation, NCC-PB0, was also 
tested for its pharmacodynamic effect (in vivo blood ChE inhibition) compared to free 
PB.  
Incubation of free PB and NCC-PB formulations supported our hypothesis that 
hydrogel formulations may prolong ChE inhibition. The NCC-PB0, NCC-PB10, and 
NCC-PB1 (which were differentiated by their crosslinking conditions) altered the time 
course of ChE inhibition minimally. The NCC-PB0 formulation inhibited significantly 
less ChE than free PB up to the 60-minute time point, after which “maximal” (i.e. same 
inhibition levels as free PB) were noted. This suggested that the NCC-PB0 formulation 
slightly retarded the release of PB. The NCC-PB10 formulation also marginally retarded 
release out to 30 minutes, while the NCC-PB1 formulation did not appear to alter PB 
release. These results are in agreement with another study which found that over 80% of 
the drug was released by 50 minutes when using a microcrystalline cellulose preparation 
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[17]. While our study did not directly evaluate PB release, we can estimate that most of 
the PB had been released from these formulations due to the levels of cholinesterase 
inhibition achieved. 
The TEMPO-PB gel formulation was the most effective in altering the time 
course of in vitro ChE inhibition. ChE inhibition was significantly lower than with free 
PB at each time point tested until 24 hours, suggesting that formulation with a 
nanocrystalline hydrogel slowed the release of PB into solution. Interestingly, however, 
the ChE inhibition achieved by the TEMPO-PB formulation plateaued around 70% 
inhibition (as compared to ~90% inhibition with free PB) at about four hours of 
incubation. This effect could be achieved by two possible mechanisms. First, the 
TEMPO-PB formulation changed the maximal amount of PB which may be released 
from the gel (i.e. some PB is irreversibly contained within the gel). Incomplete release of 
loaded drug within cellulose formulation has been observed previously [17]. Second, 
following a “burst” release, the rate of PB released from TEMPO-PB gels proceeds 
slowly out to 24 hours, at a rate which closely equals the reactivation rate of PB-inhibited 
ChE. Carbamylated enzymes spontaneously reactivate with a half-life of 15-30 minutes 
in vitro [195]. If this were the case, the 70% inhibition level achieved should persist at 
later time points. Moreover, direct evaluation of PB release from the hydrogel 
formulations would provide insight into nature of the PB release rate.  
The NCC-PB0 formulation was used for in vivo evaluation of the 
pharmacodynamic effect of PB release. While other studies have found that cellulose 
formulations alter oral absorption and bioavailability [326], we did not find any 
differences in these parameters between NCC-PB0 and free PB. The burst effect, wherein 
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a large bolus of drug releases prior to achieving a stable drug release rate, is a well-
known phenomenon in controlled release research [327]. Methods such as excipient 
coating, decreasing pore size, altering surface hydrophobicity, and others have been 
incorporated into controlled release formulations to offset this effect [328-331]. It is 
therefore possible that further tuning of the hydrogel formulations, either by chemical or 
mechanical means, could result in more desirable release kinetics. Despite this, the NCC-
PB0 preparation appeared to elicit slightly higher levels of inhibition following the 
absorption phase (Fig. 5-9). Analysis of the data after peak ChE inhibition was achieved 
(i.e. after three hours) showed ChE inhibition was increased at the 380-minute time point 
compared to free PB. This supports the suggestion that the effect of PB may be slightly 
extended by hydrogel formulation, similar to what was found in the in vitro studies.  
Toxicity arising from PB overdose is another mechanism of evaluating 
differences in pharmacokinetic/pharmacodynamics of free PB and cellulose formulated 
PB. Soldiers taking PB during the Gulf War reported minor symptoms of 
anticholinesterase toxicity including frequent urination and gastrointestinal upset [204]. 
An extended release formulation may avoid some of these side effects as ChE inhibition 
is not expected to peak as sharply. Though our biochemical data did not support the goal 
of slower absorption or decreased maximal concentration, we observed that symptoms of 
toxicity were decreased in animals which had been given the NCC-PB0 formulation. The 
51.3 mg/kg dosing level resulted in severe signs of toxicity and death within one hour for 
an animal given free PB, while the animal given the NCC-PB0 formulation survived after 
showing mild-to-moderate signs of toxicity. A similar result was also found at the 39.5 
mg/kg dosing level. While animals were generally able to survive higher doses than free 
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PB, an accurate maximum tolerated dose for NCC-PB0 was difficult to determine. In our 
preliminary studies individual animals were able to survive doses up to 51.3 mg/kg, but 
in subsequent studies some lethality was noted at much lower doses (25.7 mg/kg and 15 
mg/kg). This may be due to differences in individual animals’ sensitivity to PB, an 
inconsistent pharmacodynamic effect of cellulose formulation, or a combination thereof.  
Hydrogel formulation with nanocellulose has been used to successfully extend the 
release of certain small molecule and protein drugs. In this study we applied this 
formulation tactic on the prophylactic drug pyridostigmine. While some results were 
promising, tuning of the formulation to delay in vivo absorption and further extend ChE 
inhibition is necessary. Our in vitro studies suggested that altered surface chemistry (e.g. 
TEMPO-oxidized cellulose) may further alter release kinetics compared to other NCC-
PB formulations, though other methods of hydrogel tuning (e.g. addition of other 
excipients) merit investigation. Overall, further in vitro and in vivo studies are necessary 
to completely characterize cellulose hydrogels as a method of delayed PB release 
formulation. An improved extended release formulation of PB would be beneficial for 









 Although the agricultural use of organophosphorus compounds has been 
decreasing, they remain easy to obtain and relatively simple to manufacture. Moreover, 
while the Chemical Weapons Convention has seemingly been effective at reducing nerve 
agent stockpiles, several incidents involving nerve agents have occurred as recently as 
2018. Individuals exposed to OP compounds, whether intentionally or inadvertently, may 
experience long-term neurological sequelae in addition to disabling acute toxicity and 
death. Improvements in post-exposure treatments are being investigated, with particular 
focus on preventing OP-induced seizures and lethality. Currently, however, prophylaxis 
against OP toxicity is the most effective method at avoiding serious complications of OP 
exposure. While this approach cannot be utilized by everyone, the potential benefit to 
soldiers and other high-risk personnel warrant further development of such drugs.
 The two primary approaches to OP prophylaxis, inhibitor-based and enzyme-based, 
work by different mechanisms. Inhibitor-based approaches employ a carbamate, typically 
pyridostigmine, to “reversibly” inhibit a small proportion of AChE which creates a pool 
of enzyme which is protected from essentially irreversible OP inhibitors. In contrast, 
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enzyme-based approaches act as a molecular “sink” which is able to interact with OP 
molecules, essentially removing them from circulation (either through irreversible 
binding or catalytic destruction) before the target enzyme can be reached. The challenges 
associated with these two approaches have been discussed herein. This study evaluated 
several different approaches to improve the pharmacokinetics or pharmacodynamics of 
the stoichiometric scavenger butyrylcholinesterase, the slow catalytic bioscavenger 
BChEG117H, and the reversible inhibitor pyridostigmine.  
 Complexation with PEG has been shown to improve BChE’s pharmacokinetics. 
Furthermore, studies have demonstrated that circulation of drugs can be prolonged by red 
blood cell attachment, which PEG functionalization could facilitate. My studies evaluated 
the effect of PLL-g-PEG complexation on BChE enzyme characteristics. We found that 
complexation decreased the catalytic efficiency of the enzyme, but had variable effects 
on the OP binding capacity of the enzyme, which is more important for bioscavenger 
evaluation. We hypothesized that the binding capacity of C-BCs is less affected with 
lipophilic compounds as compared to hydrophilic compounds. However, more inhibitors 
would need to be evaluated to confirm this hypothesis, and whether or not this could have 
biological importance. Lastly, we determined that the complexation of the enzyme made 
it more resistant to inactivation by heat and proteases. Taken together, these findings 
suggest that copolymer-complexation results in both favorable and slightly unfavorable 
outcomes.  
 Next, we utilized computational re-engineering techniques aiming to improve the 
OP turnover rate of the mutant enzyme BChEG117H. We successfully produced mutants of 
BChEG117H which had a three-residue insertion on a hyper-mobile surface loop (278-285) 
 
 141 
of the enzyme. While the mutants were catalytically active, they exhibited decreased 
activity with both choline and OP substrates compared to BChEG117H. Interestingly, some 
of the loop-mutant enzymes had increased binding affinity for paraoxon, an effect that 
was also observed in silico. Moreover, one of the tested loop-mutants, ENA, had an 
increased ability to reactivate after paraoxon exposure. Computational results suggested 
that all of the OP substrates tested were unstable within the active site, making significant 
improvements in the catalytic rate futile unless the binding pocket is made more secure. 
Previous literature has suggested, however, that this is not easily done. While the results 
of this study did not point to improved catalytic activity, they may provide proof-of-
concept for catalytic improvement of other bioscavenging enzymes. We hypothesize that 
application of this method on a catalytic bioscavenger with higher intrinsic catalytic 
activity (e.g. paraoxonase) may lead to more relevant changes in catalysis as the active 
site is already optimized for catalysis of OP compounds.  
 Our final aim was focused on prophylaxis with the inhibitor pyridostigmine. We 
sought to develop an extended-release nanocrystalline cellulose hydrogel formulation of 
PB with the goal of improving upon the current recommended 8-hour dosing schedule. 
The cellulose formulation tested in this study did not decrease the absorption rate or 
maximal concentration achieved in vivo, but following this “peak”, higher ChE inhibition 
was maintained during early time points. In vitro studies suggested that TEMPO-oxidized 
cellulose gels may have a better release profile than the original cellulose formulation; 
however, an in vivo study would be necessary to confirm this. Further pharmacokinetic 
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